1
|
Geulayov G, Casey D, Bale L, Brand F, Clements C, Kapur N, Ness J, Waters K, White S, Hawton K. Variation in the clinical management of self-harm by area-level socio-economic deprivation: findings from the multicenter study of self-harm in England. Psychol Med 2024; 54:1004-1015. [PMID: 37905705 DOI: 10.1017/s0033291723002799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2023]
Abstract
BACKGROUND We investigated disparities in the clinical management of self-harm following hospital presentation with self-harm according to level of socio-economic deprivation (SED) in England. METHODS 108 092 presentations to hospitals (by 57 306 individuals) after self-harm in the Multicenter Study of Self-harm spanning 17 years. Area-level SED was based on the English Index of Multiple Deprivation. Information about indicators of clinical care was obtained from each hospital's self-harm monitoring systems. We assessed the associations of SED with indicators of care using mixed effect models. RESULTS Controlling for confounders, psychosocial assessment and admission to a general medical ward were less likely for presentations by patients living in more deprived areas relative to presentations by patients from the least deprived areas. Referral for outpatient mental health care was less likely for presentations by patients from the two most deprived localities (most deprived: adjusted odd ratio [aOR] 0.77, 95% CI 0.71-0.83, p < 0.0001; 2nd most deprived: aOR 0.80, 95% CI 0.74-0.87, p < 0.0001). Referral to substance use services and 'other' services increased with increased SED. Overall, referral for aftercare was less likely following presentations by patients living in the two most deprived areas (most deprived: aOR 0.85, 95% CI 0.78-0.92, p < 0.0001; 2nd most deprived: aOR 0.86, 95% CI 0.79-0.94, p = 0.001). CONCLUSIONS SED is associated with differential care for patients who self-harm in England. Inequalities in care may exacerbate the risk of adverse outcomes in this disadvantaged population. Further work is needed to understand the reasons for these differences and ways of providing more equitable care.
Collapse
Affiliation(s)
- G Geulayov
- Centre for Suicide Research, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
| | - D Casey
- Centre for Suicide Research, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
| | - L Bale
- Centre for Suicide Research, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
| | - F Brand
- Centre for Suicide Research, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
| | - C Clements
- Centre for Mental Health and Safety, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
| | - N Kapur
- Centre for Mental Health and Safety, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
- Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK
- NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester, UK
| | - J Ness
- Centre for Self-harm and Suicide Prevention Research, Derbyshire Healthcare NHS Foundation Trust, Derby, UK
| | - K Waters
- Centre for Self-harm and Suicide Prevention Research, Derbyshire Healthcare NHS Foundation Trust, Derby, UK
| | - S White
- MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
| | - K Hawton
- Centre for Suicide Research, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
- Oxford Health NHS Foundation Trust, Oxford, UK
| |
Collapse
|
2
|
Ainabayev A, Walls B, Mullarkey D, Caffrey D, Fleischer K, Smith CM, McGlinchey A, Casey D, McCormack SJ, Shvets I. High-performance p-type V 2O 3 films by spray pyrolysis for transparent conducting oxide applications. Sci Rep 2024; 14:1928. [PMID: 38253799 PMCID: PMC10803729 DOI: 10.1038/s41598-024-52024-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 01/12/2024] [Indexed: 01/24/2024] Open
Abstract
High-quality epitaxial p-type V2O3 thin films have been synthesized by spray pyrolysis. The films exhibited excellent electrical performance, with measurable mobility and high carrier concentration. The conductivity of the films varied between 115 and 1079 Scm-1 while the optical transparency of the films ranged from 32 to 65% in the visible region. The observed limitations in thinner films' mobility were attributed to the nanosized granular structure and the presence of two preferred growth orientations. The 60 nm thick V2O3 film demonstrated a highly competitive transparency-conductivity figure of merit compared to the state-of-the-art.
Collapse
Affiliation(s)
- Ardak Ainabayev
- School of Physics, Trinity College Dublin, College Green, Dublin 2, Dublin, D02 PN40, Ireland.
- Centre for Research On Adaptive Nanostructures and Nanodevices, Trinity College Dublin, 43 Pearse St, Dublin 2, Dublin, D02 W085, Ireland.
- Nazarbayev University, Qabanbay Batyr Ave 53, Astana, 010000, Kazakhstan.
| | - Brian Walls
- School of Physics, Trinity College Dublin, College Green, Dublin 2, Dublin, D02 PN40, Ireland
- Centre for Research On Adaptive Nanostructures and Nanodevices, Trinity College Dublin, 43 Pearse St, Dublin 2, Dublin, D02 W085, Ireland
| | - Daragh Mullarkey
- School of Physics, Trinity College Dublin, College Green, Dublin 2, Dublin, D02 PN40, Ireland
- Centre for Research On Adaptive Nanostructures and Nanodevices, Trinity College Dublin, 43 Pearse St, Dublin 2, Dublin, D02 W085, Ireland
| | - David Caffrey
- School of Physics, Trinity College Dublin, College Green, Dublin 2, Dublin, D02 PN40, Ireland
- Centre for Research On Adaptive Nanostructures and Nanodevices, Trinity College Dublin, 43 Pearse St, Dublin 2, Dublin, D02 W085, Ireland
| | - Karsten Fleischer
- Advanced Processing Technology Research Centre, Dublin City University, Glasnevin, Dublin, D09 K2WA, Ireland
| | - Christopher M Smith
- School of Physics, Trinity College Dublin, College Green, Dublin 2, Dublin, D02 PN40, Ireland
- Centre for Research On Adaptive Nanostructures and Nanodevices, Trinity College Dublin, 43 Pearse St, Dublin 2, Dublin, D02 W085, Ireland
| | - Amy McGlinchey
- School of Physics, Trinity College Dublin, College Green, Dublin 2, Dublin, D02 PN40, Ireland
- Centre for Research On Adaptive Nanostructures and Nanodevices, Trinity College Dublin, 43 Pearse St, Dublin 2, Dublin, D02 W085, Ireland
| | - Daniel Casey
- School of Physics, Trinity College Dublin, College Green, Dublin 2, Dublin, D02 PN40, Ireland
- Centre for Research On Adaptive Nanostructures and Nanodevices, Trinity College Dublin, 43 Pearse St, Dublin 2, Dublin, D02 W085, Ireland
| | - Sarah J McCormack
- Department of Civil, Structural and Environmental Engineering, School of Engineering, Trinity College Dublin, College Green, Dublin, D02 PN40, Ireland
| | - Igor Shvets
- School of Physics, Trinity College Dublin, College Green, Dublin 2, Dublin, D02 PN40, Ireland
- Centre for Research On Adaptive Nanostructures and Nanodevices, Trinity College Dublin, 43 Pearse St, Dublin 2, Dublin, D02 W085, Ireland
| |
Collapse
|
3
|
Casey D, MacGowan B, Hurricane O, Landen O, Nora R, Haan S, Kritcher A, Zylstra A, Ralph J, Dewald E, Hohenberger M, Pak A, Springer P, Weber C, Milovich J, Divol L, Hartouni E, Bionta R, Hahn K, Schlossberg D, Moore A, Gatu Johnson M. Diagnosing the origin and impact of low-mode asymmetries in ignition experiments at the National Ignition Facility. Phys Rev E 2023; 108:L053203. [PMID: 38115512 DOI: 10.1103/physreve.108.l053203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Accepted: 10/17/2023] [Indexed: 12/21/2023]
Abstract
Inertial confinement fusion ignition requires high inflight shell velocity, good energy coupling between the hotspot and shell, and high areal density at peak compression. Three-dimensional asymmetries caused by imperfections in the drive symmetry or target can grow and damage the coupling and confinement. Recent high-yield experiments have shown that low-mode asymmetries are a key degradation mechanism and contribute to variability. We show the experimental signatures and impacts of asymmetry change with increasing implosion yield given the same initial cause. This letter has implications for improving robustness to a key degradation in ignition experiments.
Collapse
Affiliation(s)
- D Casey
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - B MacGowan
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - O Hurricane
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - O Landen
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - R Nora
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - S Haan
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - A Kritcher
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - A Zylstra
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - J Ralph
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - E Dewald
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - M Hohenberger
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - A Pak
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - P Springer
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - C Weber
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - J Milovich
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - L Divol
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - E Hartouni
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - R Bionta
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - K Hahn
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - D Schlossberg
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - A Moore
- Lawrence Livermore National Laboratory, Livermore, CA 94550, USA
| | - M Gatu Johnson
- Massachusetts Institute of Technology (MIT), Cambridge, 02139 Massachusetts, USA
| |
Collapse
|
4
|
Hu A, Casey D, Toyoji M, Brown A, Elsenboss C. A Data-Driven Approach to Allocating Personal Protective Equipment During the COVID-19 Pandemic in King County, Washington. Health Secur 2023; 21:156-163. [PMID: 36716272 DOI: 10.1089/hs.2022.0115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
From the Field is a semiregular column that provides insight into the experiences of local, county, or state health professionals on the frontlines of health emergencies. National Association of County and City Health Officials members share the challenges faced and the solutions developed as they prepared for and responded to disasters, epidemics, and other major health issues. The aim of sharing these practical experiences is to provide other public health champions with the information and tools they need to help keep their communities safe even in extreme situations. The COVID-19 pandemic created an extraordinarily high demand for personal protective equipment (PPE). Acute need and supply chain disruptions made hospitals, emergency medical services, and other critical care agencies particularly vulnerable to PPE shortages. In March 2020, King County, Washington, developed computational tools, operating procedures, and data visualizations to fulfill its responsibilities to prioritize, allocate, and distribute scarce PPE equitably and efficiently during a public health emergency. King County distributed over 1.6 million gowns, 22 million gloves, 3.9 million surgical masks, and 1.5 million N95 respirators (among other items) during its PPE distribution mission. An algorithm processed resource requests from the community, with respect to available inventory, emergency allocation policies, prioritization constraints, estimated PPE use rates, agency-specific needs, and other parameters. With these inputs and constraints, the requests were translated into instructions for fulfillment and delivery and several tabular and graphical data visualizations were produced for quality assurance and transparency. Access to timely, relevant, and stable data was a constant challenge, and constraints invariably changed as the emergency response unfolded. King County's PPE distribution mission provides a useful case study in how to develop a scalable and data-driven approach to resource allocation and distribution under emergency response conditions.
Collapse
Affiliation(s)
- Audrey Hu
- Audrey E. Hu, MPH, is an Epidemiologist, Washington State Department of Health, Seattle, WA
| | - Daniel Casey
- Daniel C Casey, MPH, is an Epidemiologists, Assessment, Policy Development, and Evaluation Unit, Public Health - Seattle & King County, Seattle, WA
| | - Mariko Toyoji
- Mariko Toyoji, MPH, is an Epidemiologists, Assessment, Policy Development, and Evaluation Unit, Public Health - Seattle & King County, Seattle, WA
| | - Alicia Brown
- Alicia T. Brown, MBA, is a Solution Architect, Data & Analytics, King County Department of Information Technology, Seattle, WA
| | - Carina Elsenboss
- Carina Elsenboss, MS, is Preparedness Director, Public Health - Seattle & King County, Seattle, WA
| |
Collapse
|
5
|
Bachmann B, MacLaren SA, Bhandarkar S, Briggs T, Casey D, Divol L, Döppner T, Fittinghoff D, Freeman M, Haan S, Hall GN, Hammel B, Hartouni E, Izumi N, Geppert-Kleinrath V, Khan S, Kozioziemski B, Krauland C, Landen O, Mariscal D, Marley E, Masse L, Meaney K, Mellos G, Moore A, Pak A, Patel P, Ratledge M, Rice N, Rubery M, Salmonson J, Sater J, Schlossberg D, Schneider M, Smalyuk VA, Trosseille C, Volegov P, Weber C, Williams GJ, Wray A. Measurement of Dark Ice-Ablator Mix in Inertial Confinement Fusion. Phys Rev Lett 2022; 129:275001. [PMID: 36638294 DOI: 10.1103/physrevlett.129.275001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 11/29/2022] [Indexed: 06/17/2023]
Abstract
We present measurements of ice-ablator mix at stagnation of inertially confined, cryogenically layered capsule implosions. An ice layer thickness scan with layers significantly thinner than used in ignition experiments enables us to investigate mix near the inner ablator interface. Our experiments reveal for the first time that the majority of atomically mixed ablator material is "dark" mix. It is seeded by the ice-ablator interface instability and located in the relatively cooler, denser region of the fuel assembly surrounding the fusion hot spot. The amount of dark mix is an important quantity as it is thought to affect both fusion fuel compression and burn propagation when it turns into hot mix as the burn wave propagates through the initially colder fuel region surrounding an igniting hot spot. We demonstrate a significant reduction in ice-ablator mix in the hot-spot boundary region when we increase the initial ice layer thickness.
Collapse
Affiliation(s)
- B Bachmann
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - S A MacLaren
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - S Bhandarkar
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - T Briggs
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - D Casey
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - L Divol
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - T Döppner
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - D Fittinghoff
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - M Freeman
- Los Alamos National Laboratory, Los Alamos, New Mexico 87544, USA
| | - S Haan
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - G N Hall
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - B Hammel
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - E Hartouni
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - N Izumi
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | | | - S Khan
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - B Kozioziemski
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - C Krauland
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - O Landen
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - D Mariscal
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - E Marley
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - L Masse
- Commissariat à l'Energie Atomique, DAM, DIF, F-91297 Arpajon, France
| | - K Meaney
- Los Alamos National Laboratory, Los Alamos, New Mexico 87544, USA
| | - G Mellos
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - A Moore
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - A Pak
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - P Patel
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - M Ratledge
- General Atomics, San Diego, California 92121, USA
| | - N Rice
- General Atomics, San Diego, California 92121, USA
| | - M Rubery
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - J Salmonson
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - J Sater
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - D Schlossberg
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - M Schneider
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - V A Smalyuk
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - C Trosseille
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - P Volegov
- Los Alamos National Laboratory, Los Alamos, New Mexico 87544, USA
| | - C Weber
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - G J Williams
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | - A Wray
- Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| |
Collapse
|
6
|
Bouhnik Y, Atreya R, Casey D, Górecki M, Baik D, Yoon SW, Kwon TS, Jang M. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment. Inflamm Bowel Dis 2022:6658536. [PMID: 35942647 DOI: 10.1093/ibd/izac160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Indexed: 12/09/2022]
Abstract
BACKGROUND Inflammatory bowel disease (IBD) guidelines recommend tumor necrosis factor-α inhibitors (TNFis) for patients who have not responded to conventional therapy, and vedolizumab in case of inadequate response to conventional therapy and/or TNFis. Recent studies have shown that vedolizumab may also be effective in the earlier treatment lines. Therefore, we conducted cost-effectiveness analyses to determine the optimal treatment sequence in patients with IBD. METHODS A Markov model with a 10-year time horizon compared the cost-effectiveness of different biologic treatment sequences in patients with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD) from the UK and French perspectives. Subcutaneous formulations of infliximab, vedolizumab, and adalimumab were evaluated. Comparative effectiveness was based on a network meta-analysis of clinical trials and real-world evidence. Costs included pharmacotherapy, surgery, adverse events, and disease management. RESULTS The results indicated that treatment sequences starting with infliximab were less costly and more effective than those starting with vedolizumab for patients with UC in the United Kingdom and France, and patients with just CD in France. For patients with CD in the United Kingdom, treatment sequences starting with infliximab resulted in better health outcomes with incremental cost-effectiveness ratios (ICERs) near the threshold. CONCLUSIONS Based on the ICERs, treatment sequences starting with infliximab are the dominant option for patients with UC in the United Kingdom, and patients with UC and CD in France. In UK patients with CD, ICERs were near the assumed "willingness to pay" threshold. These results reinforce the UK's National Institute for Health and Care Excellence recommendations for using infliximab prior to using vedolizumab in biologics-naïve patients.
Collapse
Affiliation(s)
- Yoram Bouhnik
- Beaujon Hospital, Department of Gastroenterology, Paris University, Clichy, France
| | - Raja Atreya
- Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
| | - Daniel Casey
- Celltrion Healthcare United Kingdom Limited, Slough, United Kingdom
| | | | - Deborah Baik
- Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea
| | - Sang Wook Yoon
- Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea
| | - Taek Sang Kwon
- Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea
| | - Minyoung Jang
- Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea
| |
Collapse
|
7
|
McDaid D, Park AL, Tsiachristas A, Brand F, Casey D, Clements C, Geulayov G, Kapur N, Ness J, Waters K, Hawton K. Cost-effectiveness of psychosocial assessment for individuals who present to hospital following self-harm in England: a model-based retrospective analysis. Eur Psychiatry 2022; 65:e16. [PMID: 35094742 PMCID: PMC8926908 DOI: 10.1192/j.eurpsy.2022.5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background Guidance in England recommends psychosocial assessment when presenting to hospital following self-harm but adherence is variable. There is some evidence suggesting that psychosocial assessment is associated with lower risk of subsequent presentation to hospital for self-harm, but the potential cost-effectiveness of psychosocial assessment for hospital-presenting self-harm is unknown. Methods A three-state four-cycle Markov model was used to assess cost-effectiveness of psychosocial assessment after self-harm compared with no assessment over 2 years. Data on risk of subsequent self-harm and hospital costs of treating self-harm were drawn from the Multicentre Study of Self-Harm in England, while estimates of effectiveness of psychosocial assessment on risk of self-harm, quality of life, and other costs were drawn from literature. Incremental cost-effectiveness ratios (ICERs) for cost per Quality Adjusted Life Year (QALY) gained were estimated. Parameter uncertainty was addressed in univariate and probabilistic sensitivity analyses. Results Cost per QALY gained from psychosocial assessment was £10,962 (95% uncertainty interval [UI] £15,538–£9,219) from the National Health Service (NHS) perspective and £9,980 (95% UI £14,538–£6,938) from the societal perspective. Results were generally robust to changes in model assumptions. The probability of the ICER being below £20,000 per QALY gained was 78%, rising to 91% with a £30,000 threshold. Conclusions Psychosocial assessment as implemented in the English NHS is likely to be cost-effective. This evidence could support adherence to NICE guidelines. However, further evidence is needed about the precise impacts of psychosocial assessment on self-harm repetition and costs to individuals and their families beyond immediate hospital stay.
Collapse
Affiliation(s)
- D McDaid
- Care Policy and Evaluation Centre, Department of Health Policy, London School of Economics and Political Science, London, UK
| | - A-L Park
- Care Policy and Evaluation Centre, Department of Health Policy, London School of Economics and Political Science, London, UK
| | - A Tsiachristas
- Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - F Brand
- Centre for Suicide Research, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.,Oxford Health NHS Foundation Trust, Oxford, UK
| | - D Casey
- Centre for Suicide Research, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
| | - C Clements
- Centre for Mental Health and Safety, University of Manchester, Manchester, UK
| | - G Geulayov
- Centre for Suicide Research, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
| | - N Kapur
- Centre for Mental Health and Safety, University of Manchester, Manchester, UK.,Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.,NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester,Manchester, UK
| | - J Ness
- Centre for Self-harm and Suicide Prevention Research, Derbyshire Healthcare NHS Foundation Trust, Derby, UK
| | - K Waters
- Centre for Self-harm and Suicide Prevention Research, Derbyshire Healthcare NHS Foundation Trust, Derby, UK
| | - K Hawton
- Centre for Suicide Research, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.,Oxford Health NHS Foundation Trust, Oxford, UK
| |
Collapse
|
8
|
Gul F, Casey D, Mainigi S, Eiger G, Niroula A. A 65-Year-Old Woman With Dyspnea After Atrial Fibrillation Ablation. Chest 2021; 159:e29-e33. [PMID: 33422237 DOI: 10.1016/j.chest.2020.07.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 07/08/2020] [Accepted: 07/30/2020] [Indexed: 11/25/2022] Open
Abstract
CASE PRESENTATION A 65-year-old woman with a history of chronic persistent atrial fibrillation, tobacco use, and COPD was admitted to the hospital 2 months after catheter ablation for persistent atrial fibrillation and dyspnea. Her dyspnea was present at rest and worsened by exertion with limitation to ambulating less than two blocks. She also endorsed a 1-month history of cough with minimally productive whitish sputum with frequent nocturnal exacerbations and orthopnea. She denied any fevers, chest pain, or hemoptysis.
Collapse
Affiliation(s)
- Fahad Gul
- Department of Internal Medicine, Albert Einstein Medical Center Ringgold standard institution, Philadelphia, PA.
| | - Daniel Casey
- Philadelphia College of Osteopathic Medicine Ringgold standard institution, Philadelphia, PA
| | - Sumeet Mainigi
- Department of Cardiology, Albert Einstein Medical Center Ringgold standard institution, Philadelphia, PA
| | - Glenn Eiger
- Department of Internal Medicine, Albert Einstein Medical Center Ringgold standard institution, Philadelphia, PA
| | - Abesh Niroula
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University Ringgold standard institution, Atlanta, GA
| |
Collapse
|
9
|
Ibrahim H, Walsh J, Casey D, Murphy J, Plant BJ, O'Leary P, Murphy DM. Recurrent asthma exacerbations: co-existing asthma and common variable immunodeficiency. J Asthma 2021; 59:1177-1180. [PMID: 33902374 DOI: 10.1080/02770903.2021.1922913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
Abstract
Common variable immunodeficiency is characterized by impaired B-cell differentiation and defective immunoglobulin production manifesting as recurrent respiratory tract infections. While the condition can masquerade as asthma, late diagnosis of CVID in known asthmatic is rarely reported. We present the case of a 43-year-old lady with recurrent episodes of wheeze, cough, sinusitis and multiple lower respiratory tract infections. Transiently responsive to antibiotics and steroids. These episodes had been occurring for many years and she had a longstanding clinical diagnosis of asthma. As part of her work up for recurrent respiratory tract infections a CT thorax was performed and demonstrated bronchiectasis. Further tests including Immunoglobulin levels revealed critically low IgG, IgM, and IgA levels. Immunoglobulin replacement therapy was commenced with a reduction in exacerbation frequency and severity, and objective improvement of asthma control. Subsequent lung function tests demonstrated reversible airflow limitation (obstructive lung function with 13% reversibility in FEV1 post-bronchodilator) consistent with asthma. Our case illustrates the importance of searching for alternate and co-existent diagnoses in patients diagnosed with asthma who are unresponsive to conventional therapy. We believe that serum immunoglobulin measurement should form a component of such a workup.
Collapse
Affiliation(s)
- H Ibrahim
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland
| | - J Walsh
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland
| | - D Casey
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland
| | - J Murphy
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland
| | - B J Plant
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.,The HRB funded Clinical Research Facility, University College Cork, Cork, Ireland
| | - P O'Leary
- The Department of Medicine, School of Medicine, University College Cork, Cork, Ireland
| | - D M Murphy
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.,The HRB funded Clinical Research Facility, University College Cork, Cork, Ireland
| |
Collapse
|
10
|
Georganos S, Brousse O, Dujardin S, Linard C, Casey D, Milliones M, Parmentier B, van Lipzig NPM, Demuzere M, Grippa T, Vanhuysse S, Mboga N, Andreo V, Snow RW, Lennert M. Modelling and mapping the intra-urban spatial distribution of Plasmodium falciparum parasite rate using very-high-resolution satellite derived indicators. Int J Health Geogr 2020; 19:38. [PMID: 32958055 PMCID: PMC7504835 DOI: 10.1186/s12942-020-00232-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 09/08/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The rapid and often uncontrolled rural-urban migration in Sub-Saharan Africa is transforming urban landscapes expected to provide shelter for more than 50% of Africa's population by 2030. Consequently, the burden of malaria is increasingly affecting the urban population, while socio-economic inequalities within the urban settings are intensified. Few studies, relying mostly on moderate to high resolution datasets and standard predictive variables such as building and vegetation density, have tackled the topic of modeling intra-urban malaria at the city extent. In this research, we investigate the contribution of very-high-resolution satellite-derived land-use, land-cover and population information for modeling the spatial distribution of urban malaria prevalence across large spatial extents. As case studies, we apply our methods to two Sub-Saharan African cities, Kampala and Dar es Salaam. METHODS Openly accessible land-cover, land-use, population and OpenStreetMap data were employed to spatially model Plasmodium falciparum parasite rate standardized to the age group 2-10 years (PfPR2-10) in the two cities through the use of a Random Forest (RF) regressor. The RF models integrated physical and socio-economic information to predict PfPR2-10 across the urban landscape. Intra-urban population distribution maps were used to adjust the estimates according to the underlying population. RESULTS The results suggest that the spatial distribution of PfPR2-10 in both cities is diverse and highly variable across the urban fabric. Dense informal settlements exhibit a positive relationship with PfPR2-10 and hotspots of malaria prevalence were found near suitable vector breeding sites such as wetlands, marshes and riparian vegetation. In both cities, there is a clear separation of higher risk in informal settlements and lower risk in the more affluent neighborhoods. Additionally, areas associated with urban agriculture exhibit higher malaria prevalence values. CONCLUSIONS The outcome of this research highlights that populations living in informal settlements show higher malaria prevalence compared to those in planned residential neighborhoods. This is due to (i) increased human exposure to vectors, (ii) increased vector density and (iii) a reduced capacity to cope with malaria burden. Since informal settlements are rapidly expanding every year and often house large parts of the urban population, this emphasizes the need for systematic and consistent malaria surveys in such areas. Finally, this study demonstrates the importance of remote sensing as an epidemiological tool for mapping urban malaria variations at large spatial extents, and for promoting evidence-based policy making and control efforts.
Collapse
Affiliation(s)
- Stefanos Georganos
- Department of Geoscience, Environment & Society, Université Libre de Bruxelles, 1050, Brussels, Belgium.
| | - Oscar Brousse
- Department of Earth and Environmental Sciences, KU Leuven, Celestijnenlaan 200E, 3001, Louvain, Belgium
| | - Sébastien Dujardin
- Institute of Life, Earth and Environment, University of Namur, 5000, Namur, Belgium
- Department of Geography, University of Namur, Rue de Bruxelles 61, 5000, Namur, Belgium
| | - Catherine Linard
- Institute of Life, Earth and Environment, University of Namur, 5000, Namur, Belgium
- Department of Geography, University of Namur, Rue de Bruxelles 61, 5000, Namur, Belgium
| | - Daniel Casey
- Senator George J. Mitchell Center for Sustainability Solutions, University of Maine, 5710 Norman Smith Hall, Orono, ME, 04469-5710, USA
| | - Marco Milliones
- Department of Geography, University of Mary Washington, 1301 College Avenue, Fredericksburg, VA, 22401, USA
| | - Benoit Parmentier
- Senator George J. Mitchell Center for Sustainability Solutions, University of Maine, 5710 Norman Smith Hall, Orono, ME, 04469-5710, USA
- Department of Geography, University of Mary Washington, 1301 College Avenue, Fredericksburg, VA, 22401, USA
| | - Nicole P M van Lipzig
- Department of Earth and Environmental Sciences, KU Leuven, Celestijnenlaan 200E, 3001, Louvain, Belgium
| | | | - Tais Grippa
- Department of Geoscience, Environment & Society, Université Libre de Bruxelles, 1050, Brussels, Belgium
| | - Sabine Vanhuysse
- Department of Geoscience, Environment & Society, Université Libre de Bruxelles, 1050, Brussels, Belgium
| | - Nicholus Mboga
- Department of Geoscience, Environment & Society, Université Libre de Bruxelles, 1050, Brussels, Belgium
| | - Verónica Andreo
- Instituto de Altos Estudios Espaciales "Mario Gulich". Comisión Nacional de Actividades Espaciales (CONAE), Universidad Nacional de Córdoba (UNC), Córdoba, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Robert W Snow
- Population and Health Unit, Kenya Medical Research Institute/Wellcome Trust Research Programme, Nairobi, Kenya
- Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Moritz Lennert
- Department of Geoscience, Environment & Society, Université Libre de Bruxelles, 1050, Brussels, Belgium
| |
Collapse
|
11
|
Casey B, Byrne M, Casey D, Gillespie P, Hobbins A, Newell J, Morrissey E, Dinneen SF. Improving Outcomes Among Young Adults with type 1 diabetes: The D1 Now Randomised Pilot Study Protocol. Diabet Med 2020; 37:1590-1604. [PMID: 32511803 DOI: 10.1111/dme.14337] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/02/2020] [Indexed: 01/10/2023]
Abstract
BACKGROUND Young adults (18-25 years old) living with type 1 diabetes mellitus often have sub-optimal glycaemic levels which can increase their risk of long term diabetes complications. Informed by health psychology theory and using a (public and patient involvement) young adult-centred approach, we have developed a complex intervention, entitled D1 Now, to improve outcomes in this target group. The D1 Now intervention includes three components; 1) a support-worker, 2) an interactive messaging system and 3) an agenda setting tool for use during clinic consultations. AIMS The aim of the D1 Now pilot study is to gather and analyse acceptability and feasibility data to allow us to (1) refine the D1 Now intervention, and (2) determine the feasibility of a definitive Randomised Control Trial (RCT) of the intervention. METHODS Diabetes clinics on the island of Ireland will be recruited and randomised to a D1 Now intervention arm or a usual care control arm. For a participant to be eligible they should be 18-25 years old and living with type 1 diabetes for at least 12 months. Participant outcomes (influenced by a Core Outcome Set) include change in HbA1c, clinic attendance, number of episodes of severe hypoglycaemia and of diabetic ketoacidosis, diabetes distress, self-management, quality of life and perceived level of control over diabetes; these will be will be measured at baseline and after 12 months follow-up for descriptive statistics only. An assessment of treatment fidelity, a health economic analysis and a qualitative sub-study will also be incorporated into the pilot study. ISRCTN (ref: ISRCTN74114336).
Collapse
Affiliation(s)
- B Casey
- Physical Activity for Health Cluster, Health Research Institute, University of Limerick, Limerick, Ireland
- Health Behaviour Change Research Group, School of Psychology, NUI Galway, Galway, Ireland
| | - M Byrne
- Health Behaviour Change Research Group, School of Psychology, NUI Galway, Galway, Ireland
| | - D Casey
- School of Nursing & Midwifery, NUI Galway, Galway, Ireland
| | - P Gillespie
- Health Economics & Policy Analysis Centre, Centre for Research in Medical Devices, NUI Galway, Galway, Ireland
| | - A Hobbins
- Centre for Research in Medical Devices (Cúram) and Health Economics and Policy Analysis Centre (HEPAC), NUI Galway, Galway, Ireland
| | - J Newell
- School of Mathematics, Statistics & Applied Mathematics, NUI Galway, Galway, Ireland
| | - E Morrissey
- Health Behaviour Change Research Group, School of Psychology, NUI Galway, Galway, Ireland
- School of Nursing & Midwifery, NUI Galway, Galway, Ireland
| | - S F Dinneen
- School of Medicine, NUI Galway, Galway, Ireland
- Centre for Diabetes Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland
| |
Collapse
|
12
|
Park Y, Casey D, Joshi I, Zhu J, Cheng F. Emergence of New Disease: How Can Artificial Intelligence Help? Trends Mol Med 2020; 26:627-629. [PMID: 32418724 PMCID: PMC7196393 DOI: 10.1016/j.molmed.2020.04.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 04/14/2020] [Accepted: 04/26/2020] [Indexed: 12/16/2022]
Abstract
Emergence of new disease remains a critical parameter in human health and society. Advances in artificial intelligence (AI) allow for rapid processing and analysis of massive and complex data. In this forum article, the recent applications across disease prediction and drug development in relation to the COVID-19 pandemic are reviewed.
Collapse
Affiliation(s)
- Yurim Park
- Radcliffe Department of Medicine, Medical Sciences Division, University of Oxford, Oxford, UK.
| | - Daniel Casey
- Innovation Faculty, Celltrion Healthcare, Slough, UK
| | - Indra Joshi
- Digital Health and Artificial Intelligence Laboratory, National Health Service, London, UK
| | - Jiming Zhu
- Vanke School of Public Health and School of Medicine, Tsinghua University, Beijing, China; Institute for Hospital Management, Tsinghua Shenzhen International Graduate School, Shenzhen, China
| | - Feng Cheng
- Vanke School of Public Health and School of Medicine, Tsinghua University, Beijing, China
| |
Collapse
|
13
|
Ibrahim H, O'Sullivan R, Casey D, Murphy J, MacSharry J, Plant BJ, Murphy DM. The effectiveness of Reslizumab in severe asthma treatment: a real-world experience. Respir Res 2019; 20:289. [PMID: 31861993 PMCID: PMC6923853 DOI: 10.1186/s12931-019-1251-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Accepted: 11/27/2019] [Indexed: 12/31/2022] Open
Abstract
Background Increased numbers of blood and sputum eosinophils are associated with higher exacerbation frequency and increased asthma severity. In clinical trials, targeting Interleukin-5 has been shown to be a useful therapeutic strategy for patients with severe eosinophilic asthma. Methods Twenty-six patients have been commenced on Reslizumab in our institution since early 2017. Safety and clinical efficacy parameters were recorded at regular intervals. Results Mean ACQ-6 score at the start of treatment was 3.5. The average number of exacerbations in the year preceding treatment was 8.3 per person. 30% of patients had been admitted to hospital at least once over the 12 months preceding therapy. 54% of our patients were on long term oral steroid. Our data showed sustained improvement of Asthma control (Mean improvement in ACQ-6 was 1.7 at 1 year, and 2.0 at 2 years, P = 0.0001). Of the patients who were on long term systemic steroids, 35.7% discontinued steroids completely, with a mean reduction of prednisolone dose of 5.2 mg at 1 year. There was a 79% reduction in the annual exacerbation frequency at 1 year, and 88% at 2 years (P = < 0.0001). Modest, albeit statistically significant increases in creatine kinase which seemed to plateau by 1 year were noted. Conclusions Overall, Reslizumab was well tolerated with discontinuation of treatment due to side effects recorded in only one patient. Our data confirm the utility of anti-IL5 therapy in a carefully selected phenotype of severe asthma with evidence of eosinophilic airway inflammation.
Collapse
Affiliation(s)
- H Ibrahim
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland
| | - R O'Sullivan
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland
| | - D Casey
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland
| | - J Murphy
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland
| | - J MacSharry
- The Schools of Medicine and Microbiology, University College Cork, Cork, Ireland
| | - B J Plant
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.,The HRB funded Clinical Research Facility, University College Cork, Cork, Ireland
| | - D M Murphy
- The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland. .,The HRB funded Clinical Research Facility, University College Cork, Cork, Ireland.
| |
Collapse
|
14
|
Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, Harris JR, Guerra CA, Thorn MP, Bisanzio D, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Lim SS, Murray CJL, Price RN, Baird JK, Smith DL, Bhatt S, Weiss DJ, Hay SI, Gething PW. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet 2019; 394:332-343. [PMID: 31229233 PMCID: PMC6675736 DOI: 10.1016/s0140-6736(19)31096-7] [Citation(s) in RCA: 221] [Impact Index Per Article: 44.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 04/12/2019] [Accepted: 04/24/2019] [Indexed: 01/12/2023]
Abstract
BACKGROUND Plasmodium vivax exacts a significant toll on health worldwide, yet few efforts to date have quantified the extent and temporal trends of its global distribution. Given the challenges associated with the proper diagnosis and treatment of P vivax, national malaria programmes-particularly those pursuing malaria elimination strategies-require up to date assessments of P vivax endemicity and disease impact. This study presents the first global maps of P vivax clinical burden from 2000 to 2017. METHODS In this spatial and temporal modelling study, we adjusted routine malariometric surveillance data for known biases and used socioeconomic indicators to generate time series of the clinical burden of P vivax. These data informed Bayesian geospatial models, which produced fine-scale predictions of P vivax clinical incidence and infection prevalence over time. Within sub-Saharan Africa, where routine surveillance for P vivax is not standard practice, we combined predicted surfaces of Plasmodium falciparum with country-specific ratios of P vivax to P falciparum. These results were combined with surveillance-based outputs outside of Africa to generate global maps. FINDINGS We present the first high-resolution maps of P vivax burden. These results are combined with those for P falciparum (published separately) to form the malaria estimates for the Global Burden of Disease 2017 study. The burden of P vivax malaria decreased by 41·6%, from 24·5 million cases (95% uncertainty interval 22·5-27·0) in 2000 to 14·3 million cases (13·7-15·0) in 2017. The Americas had a reduction of 56·8% (47·6-67·0) in total cases since 2000, while South-East Asia recorded declines of 50·5% (50·3-50·6) and the Western Pacific regions recorded declines of 51·3% (48·0-55·4). Europe achieved zero P vivax cases during the study period. Nonetheless, rates of decline have stalled in the past five years for many countries, with particular increases noted in regions affected by political and economic instability. INTERPRETATION Our study highlights important spatial and temporal patterns in the clinical burden and prevalence of P vivax. Amid substantial progress worldwide, plateauing gains and areas of increased burden signal the potential for challenges that are greater than expected on the road to malaria elimination. These results support global monitoring systems and can inform the optimisation of diagnosis and treatment where P vivax has most impact. FUNDING Bill & Melinda Gates Foundation and the Wellcome Trust.
Collapse
Affiliation(s)
- Katherine E Battle
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Tim C D Lucas
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Michele Nguyen
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Rosalind E Howes
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Anita K Nandi
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Katherine A Twohig
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Daniel A Pfeffer
- Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia
| | - Ewan Cameron
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Puja C Rao
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Daniel Casey
- Seattle & King County Public Health, Seattle, WA, USA
| | - Harry S Gibson
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Jennifer A Rozier
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | | | - Suzanne H Keddie
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Emma L Collins
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Joseph R Harris
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Carlos A Guerra
- Medical Care Development International, Silver Spring, MD, USA
| | - Michael P Thorn
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Donal Bisanzio
- Global Health Division, RTI International, Washington, DC, USA; Epidemiology and Public Health Division, School of Medicine, University of Nottingham, Nottingham, UK
| | - Nancy Fullman
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Chantal K Huynh
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Xie Kulikoff
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Michael J Kutz
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Alan D Lopez
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Ali H Mokdad
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Grant Nguyen
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | | | - Theo Vos
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Haidong Wang
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Stephen S Lim
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | | | - Ric N Price
- Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - J Kevin Baird
- Eijkman-Oxford Clinical Rearch Unit, Jakarta, Indonesia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - David L Smith
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | | | - Daniel J Weiss
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Simon I Hay
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Peter W Gething
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.
| |
Collapse
|
15
|
Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, Cameron E, Twohig KA, Pfeffer DA, Rozier JA, Gibson HS, Rao PC, Casey D, Bertozzi-Villa A, Collins EL, Dalrymple U, Gray N, Harris JR, Howes RE, Kang SY, Keddie SH, May D, Rumisha S, Thorn MP, Barber R, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Smith DL, Lim SS, Murray CJL, Bhatt S, Hay SI, Gething PW. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000-17: a spatial and temporal modelling study. Lancet 2019; 394:322-331. [PMID: 31229234 PMCID: PMC6675740 DOI: 10.1016/s0140-6736(19)31097-9] [Citation(s) in RCA: 216] [Impact Index Per Article: 43.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 04/12/2019] [Accepted: 04/24/2019] [Indexed: 01/26/2023]
Abstract
BACKGROUND Since 2000, the scale-up of malaria control interventions has substantially reduced morbidity and mortality caused by the disease globally, fuelling bold aims for disease elimination. In tandem with increased availability of geospatially resolved data, malaria control programmes increasingly use high-resolution maps to characterise spatially heterogeneous patterns of disease risk and thus efficiently target areas of high burden. METHODS We updated and refined the Plasmodium falciparum parasite rate and clinical incidence models for sub-Saharan Africa, which rely on cross-sectional survey data for parasite rate and intervention coverage. For malaria endemic countries outside of sub-Saharan Africa, we produced estimates of parasite rate and incidence by applying an ecological downscaling approach to malaria incidence data acquired via routine surveillance. Mortality estimates were derived by linking incidence to systematically derived vital registration and verbal autopsy data. Informed by high-resolution covariate surfaces, we estimated P falciparum parasite rate, clinical incidence, and mortality at national, subnational, and 5 × 5 km pixel scales with corresponding uncertainty metrics. FINDINGS We present the first global, high-resolution map of P falciparum malaria mortality and the first global prevalence and incidence maps since 2010. These results are combined with those for Plasmodium vivax (published separately) to form the malaria estimates for the Global Burden of Disease 2017 study. The P falciparum estimates span the period 2000-17, and illustrate the rapid decline in burden between 2005 and 2017, with incidence declining by 27·9% and mortality declining by 42·5%. Despite a growing population in endemic regions, P falciparum cases declined between 2005 and 2017, from 232·3 million (95% uncertainty interval 198·8-277·7) to 193·9 million (156·6-240·2) and deaths declined from 925 800 (596 900-1 341 100) to 618 700 (368 600-952 200). Despite the declines in burden, 90·1% of people within sub-Saharan Africa continue to reside in endemic areas, and this region accounted for 79·4% of cases and 87·6% of deaths in 2017. INTERPRETATION High-resolution maps of P falciparum provide a contemporary resource for informing global policy and malaria control planning, programme implementation, and monitoring initiatives. Amid progress in reducing global malaria burden, areas where incidence trends have plateaued or increased in the past 5 years underscore the fragility of hard-won gains against malaria. Efforts towards elimination should be strengthened in such areas, and those where burden remained high throughout the study period. FUNDING Bill & Melinda Gates Foundation.
Collapse
Affiliation(s)
- Daniel J Weiss
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Tim C D Lucas
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Michele Nguyen
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Anita K Nandi
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Donal Bisanzio
- Global Health Division, Research Triangle Institute International, Washington, DC, USA; Public Health Division, School of Medicine, University of Nottingham, Nottingham, UK
| | - Katherine E Battle
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Ewan Cameron
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Katherine A Twohig
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Daniel A Pfeffer
- Menzies School of Health Research, Charles Darwin University, Casuarina, NT, Australia
| | - Jennifer A Rozier
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Harry S Gibson
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Puja C Rao
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Daniel Casey
- Seattle and King County Public Health, Seattle, WA, USA
| | | | - Emma L Collins
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Ursula Dalrymple
- Public Health England, Department of Health and Social Care, London, UK
| | - Naomi Gray
- Instruct: An Integrated Structural Biology Infrastructure for Europe, Oxford, UK
| | - Joseph R Harris
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Rosalind E Howes
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Sun Yun Kang
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Suzanne H Keddie
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Daniel May
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Susan Rumisha
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Michael P Thorn
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
| | - Ryan Barber
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Nancy Fullman
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Chantal K Huynh
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Xie Kulikoff
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Michael J Kutz
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Alan D Lopez
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Ali H Mokdad
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Grant Nguyen
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | | | - Theo Vos
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Haidong Wang
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - David L Smith
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Stephen S Lim
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | | | | | - Simon I Hay
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - Peter W Gething
- Malaria Atlas Project, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.
| |
Collapse
|
16
|
Breton A, Casey D, Arnaoutoglou NA. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatry 2019; 34:233-242. [PMID: 30370616 DOI: 10.1002/gps.5016] [Citation(s) in RCA: 114] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Accepted: 10/18/2018] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Mild cognitive impairment (MCI) is regarded as a prodrome to dementia. Various cognitive tests can help with diagnosis; meta-analysis of diagnostic accuracy studies would assist clinicians in choosing optimal tests. METHODS We searched online databases for "mild cognitive impairment" and "diagnosis" or "screening" from 01/01/1999 to 01/07/2017. Articles assessing the diagnostic accuracy of a cognitive test compared with standard diagnostic criteria were extracted. Risk of bias was assessed. Bivariate random-effects meta-analysis was used to evaluate sensitivity and specificity. RESULTS Eight cognitive tests (ACE-R, CERAD, CDT-Sunderland, IQCODE, Memory Alteration Test, MMSE, MoCA, and Qmci) were considered for meta-analysis. ACE-R, CERAD, MoCA, and Qmci were found to have similar diagnostic accuracy, while the MMSE had lower sensitivity. Memory Alteration Test had the highest sensitivity and equivalent specificity to the other tests. DISCUSSION Multiple cognitive tests have comparable diagnostic accuracy. The Memory Alteration Test is short and has the highest sensitivity. New cognitive tests for MCI diagnosis should not be compared with the MMSE.
Collapse
Affiliation(s)
- Alexandre Breton
- Medical School, Medical Sciences Division, University of Oxford, Oxford, UK
| | | | - Nikitas A Arnaoutoglou
- Department of Psychiatry, University of Oxford, Oxford, UK.,Department of Psychiatry, University of Cambridge, Cambridge, UK
| |
Collapse
|
17
|
McCleery J, Molena EJ, Worrall RE, Pflanz CP, Casey D. Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's disease. Hippokratia 2018. [DOI: 10.1002/14651858.cd010188.pub2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Jenny McCleery
- Oxford Health NHS Foundation Trust; Elms Centre Oxford Road Banbury Oxfordshire UK OX16 9AL
| | - Emma J Molena
- Oxford University Medical School; Wadham College Parks Road Oxford UK OX13PN
| | | | | | - Daniel Casey
- Merton College, University of Oxford; Oxford UK OX1 4JD
| |
Collapse
|
18
|
Le Pape S, Berzak Hopkins LF, Divol L, Pak A, Dewald EL, Bhandarkar S, Bennedetti LR, Bunn T, Biener J, Crippen J, Casey D, Edgell D, Fittinghoff DN, Gatu-Johnson M, Goyon C, Haan S, Hatarik R, Havre M, Ho DDM, Izumi N, Jaquez J, Khan SF, Kyrala GA, Ma T, Mackinnon AJ, MacPhee AG, MacGowan BJ, Meezan NB, Milovich J, Millot M, Michel P, Nagel SR, Nikroo A, Patel P, Ralph J, Ross JS, Rice NG, Strozzi D, Stadermann M, Volegov P, Yeamans C, Weber C, Wild C, Callahan D, Hurricane OA. Fusion Energy Output Greater than the Kinetic Energy of an Imploding Shell at the National Ignition Facility. Phys Rev Lett 2018; 120:245003. [PMID: 29956968 DOI: 10.1103/physrevlett.120.245003] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 05/04/2018] [Indexed: 06/08/2023]
Abstract
A series of cryogenic, layered deuterium-tritium (DT) implosions have produced, for the first time, fusion energy output twice the peak kinetic energy of the imploding shell. These experiments at the National Ignition Facility utilized high density carbon ablators with a three-shock laser pulse (1.5 MJ in 7.5 ns) to irradiate low gas-filled (0.3 mg/cc of helium) bare depleted uranium hohlraums, resulting in a peak hohlraum radiative temperature ∼290 eV. The imploding shell, composed of the nonablated high density carbon and the DT cryogenic layer, is, thus, driven to velocity on the order of 380 km/s resulting in a peak kinetic energy of ∼21 kJ, which once stagnated produced a total DT neutron yield of 1.9×10^{16} (shot N170827) corresponding to an output fusion energy of 54 kJ. Time dependent low mode asymmetries that limited further progress of implosions have now been controlled, leading to an increased compression of the hot spot. It resulted in hot spot areal density (ρr∼0.3 g/cm^{2}) and stagnation pressure (∼360 Gbar) never before achieved in a laboratory experiment.
Collapse
Affiliation(s)
- S Le Pape
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L F Berzak Hopkins
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L Divol
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Pak
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - E L Dewald
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Bhandarkar
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L R Bennedetti
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Bunn
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Biener
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Crippen
- General Atomics, San Diego, California 92186, USA
| | - D Casey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Edgell
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14636, USA
| | - D N Fittinghoff
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Gatu-Johnson
- Plasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C Goyon
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Haan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R Hatarik
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Havre
- General Atomics, San Diego, California 92186, USA
| | - D D-M Ho
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - N Izumi
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Jaquez
- General Atomics, San Diego, California 92186, USA
| | - S F Khan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - G A Kyrala
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - T Ma
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A J Mackinnon
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A G MacPhee
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B J MacGowan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - N B Meezan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Milovich
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Millot
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - P Michel
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S R Nagel
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Nikroo
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - P Patel
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Ralph
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J S Ross
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - N G Rice
- General Atomics, San Diego, California 92186, USA
| | - D Strozzi
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Stadermann
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - P Volegov
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - C Yeamans
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Weber
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Wild
- Diamond Materials Gmbh, 79108 Freiburg, Germany
| | - D Callahan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O A Hurricane
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| |
Collapse
|
19
|
Verma S, Wolkenstein P, Le L, Lee J, Widemann B, Brownell I, Jarnagin K, Lavker R, Legius E, Anderson R, Plotkin S, Weinberg H, Casey D, Ko H, LaRosa S, Knight P, Parides M, Bora N, Morris J, Riccardi V, Korf B, Blakeley J. LB951 Establishing a roadmap for therapeutics development for cutaneous neurofibromas. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Barber RM, Fullman N, Sorensen RJD, Bollyky T, McKee M, Nolte E, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulle AM, Abdurahman AA, Abera SF, Abraham B, Abreha GF, Adane K, Adelekan AL, Adetifa IMO, Afshin A, Agarwal A, Agarwal SK, Agarwal S, Agrawal A, Kiadaliri AA, Ahmadi A, Ahmed KY, Ahmed MB, Akinyemi RO, Akinyemiju TF, Akseer N, Al-Aly Z, Alam K, Alam N, Alam SS, Alemu ZA, Alene KA, Alexander L, Ali R, Ali SD, Alizadeh-Navaei R, Alkerwi A, Alla F, Allebeck P, Allen C, Al-Raddadi R, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzman N, Amare AT, Amini E, Ammar W, Amo-Adjei J, Amoako YA, Anderson BO, Androudi S, Ansari H, Ansha MG, Antonio CAT, Ärnlöv J, Artaman A, Asayesh H, Assadi R, Astatkie A, Atey TM, Atique S, Atnafu NT, Atre SR, Avila-Burgos L, Avokpaho EFGA, Quintanilla BPA, Awasthi A, Ayele NN, Azzopardi P, Saleem HOB, Bärnighausen T, Bacha U, Badawi A, Banerjee A, Barac A, Barboza MA, Barker-Collo SL, Barrero LH, Basu S, Baune BT, Baye K, Bayou YT, Bazargan-Hejazi S, Bedi N, Beghi E, Béjot Y, Bello AK, Bennett DA, Bensenor IM, Berhane A, Bernabé E, Bernal OA, Beyene AS, Beyene TJ, Bhutta ZA, Biadgilign S, Bikbov B, Birlik SM, Birungi C, Biryukov S, Bisanzio D, Bizuayehu HM, Bose D, Brainin M, Brauer M, Brazinova A, Breitborde NJK, Brenner H, Butt ZA, Cárdenas R, Cahuana-Hurtado L, Campos-Nonato IR, Car J, Carrero JJ, Casey D, Caso V, Castañeda-Orjuela CA, Rivas JC, Catalá-López F, Cecilio P, Cercy K, Charlson FJ, Chen AZ, Chew A, Chibalabala M, Chibueze CE, Chisumpa VH, Chitheer AA, Chowdhury R, Christensen H, Christopher DJ, Ciobanu LG, Cirillo M, Coggeshall MS, Cooper LT, Cortinovis M, Crump JA, Dalal K, Danawi H, Dandona L, Dandona R, Dargan PI, das Neves J, Davey G, Davitoiu DV, Davletov K, De Leo D, Del Gobbo LC, del Pozo-Cruz B, Dellavalle RP, Deribe K, Deribew A, Des Jarlais DC, Dey S, Dharmaratne SD, Dicker D, Ding EL, Dokova K, Dorsey ER, Doyle KE, Dubey M, Ehrenkranz R, Ellingsen CL, Elyazar I, Enayati A, Ermakov SP, Eshrati B, Esteghamati A, Estep K, Fürst T, Faghmous IDA, Fanuel FBB, Faraon EJA, Farid TA, Farinha CSES, Faro A, Farvid MS, Farzadfar F, Feigin VL, Feigl AB, Fereshtehnejad SM, Fernandes JG, Fernandes JC, Feyissa TR, Fischer F, Fitzmaurice C, Fleming TD, Foigt N, Foreman KJ, Forouzanfar MH, Franklin RC, Frostad J, G/hiwot TT, Gakidou E, Gambashidze K, Gamkrelidze A, Gao W, Garcia-Basteiro AL, Gebre T, Gebremedhin AT, Gebremichael MW, Gebru AA, Gelaye AA, Geleijnse JM, Genova-Maleras R, Gibney KB, Giref AZ, Gishu MD, Giussani G, Godwin WW, Gold A, Goldberg EM, Gona PN, Goodridge A, Gopalani SV, Goto A, Graetz N, Greaves F, Griswold M, Guban PI, Gugnani HC, Gupta PC, Gupta R, Gupta R, Gupta T, Gupta V, Habtewold TD, Hafezi-Nejad N, Haile D, Hailu AD, Hailu GB, Hakuzimana A, Hamadeh RR, Hambisa MT, Hamidi S, Hammami M, Hankey GJ, Hao Y, Harb HL, Hareri HA, Haro JM, Hassanvand MS, Havmoeller R, Hay RJ, Hay SI, Hendrie D, Heredia-Pi IB, Hoek HW, Horino M, Horita N, Hosgood HD, Htet AS, Hu G, Huang H, Huang JJ, Huntley BM, Huynh C, Iburg KM, Ileanu BV, Innos K, Irenso AA, Jahanmehr N, Jakovljevic MB, James P, James SL, Javanbakht M, Jayaraman SP, Jayatilleke AU, Jeemon P, Jha V, John D, Johnson C, Johnson SC, Jonas JB, Juel K, Kabir Z, Kalkonde Y, Kamal R, Kan H, Karch A, Karema CK, Karimi SM, Kasaeian A, Kassebaum NJ, Kastor A, Katikireddi SV, Kazanjan K, Keiyoro PN, Kemmer L, Kemp AH, Kengne AP, Kerbo AA, Kereselidze M, Kesavachandran CN, Khader YS, Khalil I, Khan AR, Khan EA, Khan G, Khang YH, Khoja ATA, Khonelidze I, Khubchandani J, Kibret GD, Kim D, Kim P, Kim YJ, Kimokoti RW, Kinfu Y, Kissoon N, Kivipelto M, Kokubo Y, Kolk A, Kolte D, Kopec JA, Kosen S, Koul PA, Koyanagi A, Kravchenko M, Krishnaswami S, Krohn KJ, Defo BK, Bicer BK, Kuipers EJ, Kulkarni VS, Kumar GA, Kumsa FA, Kutz M, Kyu HH, Lager ACJ, Lal A, Lal DK, Lalloo R, Lallukka T, Lan Q, Langan SM, Lansingh VC, Larson HJ, Larsson A, Laryea DO, Latif AA, Lawrynowicz AEB, Leasher JL, Leigh J, Leinsalu M, Leshargie CT, Leung J, Leung R, Levi M, Liang X, Lim SS, Lind M, Linn S, Lipshultz SE, Liu P, Liu Y, Lo LT, Logroscino G, Lopez AD, Lorch SA, Lotufo PA, Lozano R, Lunevicius R, Lyons RA, Macarayan ERK, Mackay MT, El Razek HMA, El Razek MMA, Mahdavi M, Majeed A, Malekzadeh R, Malta DC, Mantovani LG, Manyazewal T, Mapoma CC, Marcenes W, Marks GB, Marquez N, Martinez-Raga J, Marzan MB, Massano J, Mathur MR, Maulik PK, Mazidi M, McAlinden C, McGrath JJ, McNellan C, Meaney PA, Mehari A, Mehndiratta MM, Meier T, Mekonnen AB, Meles KG, Memish ZA, Mengesha MM, Mengiste DT, Mengistie MA, Menota BG, Mensah GA, Mereta ST, Meretoja A, Meretoja TJ, Mezgebe HB, Micha R, Millear A, Mills EJ, Minnig S, Mirarefin M, Mirrakhimov EM, Mock CN, Mohammad KA, Mohammed S, Mohanty SK, Mokdad AH, Mola GLD, Molokhia M, Monasta L, Montico M, Moradi-Lakeh M, Moraga P, Morawska L, Mori R, Moses M, Mueller UO, Murthy S, Musa KI, Nachega JB, Nagata C, Nagel G, Naghavi M, Naheed A, Naldi L, Nangia V, Nascimento BR, Negoi I, Neupane SP, Newton CR, Ng M, Ngalesoni FN, Ngunjiri JW, Nguyen G, Ningrum DNA, Nolte S, Nomura M, Norheim OF, Norrving B, Noubiap JJN, Obermeyer CM, Ogbo FA, Oh IH, Okoro A, Oladimeji O, Olagunju AT, Olivares PR, Olsen HE, Olusanya BO, Olusanya JO, Opio JN, Oren E, Ortiz A, Osborne RH, Osman M, Owolabi MO, PA M, Pain AW, Pakhale S, Castillo EP, Pana A, Papachristou C, Parsaeian M, Patel T, Patton GC, Paudel D, Paul VK, Pearce N, Pereira DM, Perez-Padilla R, Perez-Ruiz F, Perico N, Pesudovs K, Petzold M, Phillips MR, Pigott DM, Pillay JD, Pinho C, Polinder S, Pond CD, Prakash V, Purwar M, Qorbani M, Quistberg DA, Radfar A, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rai RK, Ram U, Rana SM, Rankin Z, Rao PV, Rao PC, Rawaf S, Rego MAS, Reitsma M, Remuzzi G, Renzaho AMNN, Resnikoff S, Rezaei S, Rezai MS, Ribeiro AL, Roba HS, Rokni MB, Ronfani L, Roshandel G, Roth GA, Rothenbacher D, Roy NK, Sachdev PS, Sackey BB, Saeedi MY, Safiri S, Sagar R, Sahraian MA, Saleh MM, Salomon JA, Samy AM, Sanabria JR, Sanchez-Niño MD, Sandar L, Santos IS, Santos JV, Milicevic MMS, Sarmiento-Suarez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Saylan MI, Schöttker B, Schutte AE, Schwebel DC, Seedat S, Seid AM, Seifu CN, Sepanlou SG, Serdar B, Servan-Mori EE, Setegn T, Shackelford KA, Shaheen A, Shahraz S, Shaikh MA, Shakh-Nazarova M, Shamsipour M, Islam SMS, Sharma J, Sharma R, She J, Sheikhbahaei S, Shen J, Shi P, Shigematsu M, Shin MJ, Shiri R, Shoman H, Shrime MG, Sibamo ELS, Sigfusdottir ID, Silva DAS, Silveira DGA, Sindi S, Singh A, Singh JA, Singh OP, Singh PK, Singh V, Sinke AH, Sinshaw AE, Skirbekk V, Sliwa K, Smith A, Sobngwi E, Soneji S, Soriano JB, Sousa TCM, Sposato LA, Sreeramareddy CT, Stathopoulou V, Steel N, Steiner C, Steinke S, Stokes MA, Stranges S, Strong M, Stroumpoulis K, Sturua L, Sufiyan MB, Suliankatchi RA, Sun J, Sur P, Swaminathan S, Sykes BL, Tabarés-Seisdedos R, Tabb KM, Taffere GR, Talongwa RT, Tarajia M, Tavakkoli M, Taveira N, Teeple S, Tegegne TK, Tehrani-Banihashemi A, Tekelab T, Tekle DY, Shifa GT, Terkawi AS, Tesema AG, Thakur JS, Thomson AJ, Tillmann T, Tiruye TY, Tobe-Gai R, Tonelli M, Topor-Madry R, Tortajada M, Troeger C, Truelsen T, Tura AK, Uchendu US, Ukwaja KN, Undurraga EA, Uneke CJ, Uthman OA, van Boven JFM, Van Dingenen R, Varughese S, Vasankari T, Venketasubramanian N, Violante FS, Vladimirov SK, Vlassov VV, Vollset SE, Vos T, Wagner JA, Wakayo T, Waller SG, Walson JL, Wang H, Wang YP, Watkins DA, Weiderpass E, Weintraub RG, Wen CP, Werdecker A, Wesana J, Westerman R, Whiteford HA, Wilkinson JD, Wiysonge CS, Woldeyes BG, Wolfe CDA, Won S, Workicho A, Workie SB, Wubshet M, Xavier D, Xu G, Yadav AK, Yaghoubi M, Yakob B, Yan LL, Yano Y, Yaseri M, Yimam HH, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Zaidi Z, El Sayed Zaki M, Zambrana-Torrelio C, Zapata T, Zenebe ZM, Zodpey S, Zoeckler L, Zuhlke LJ, Murray CJL. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet 2017; 390:231-266. [PMID: 28528753 PMCID: PMC5528124 DOI: 10.1016/s0140-6736(17)30818-8] [Citation(s) in RCA: 307] [Impact Index Per Article: 43.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Revised: 02/26/2017] [Accepted: 02/28/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND National levels of personal health-care access and quality can be approximated by measuring mortality rates from causes that should not be fatal in the presence of effective medical care (ie, amenable mortality). Previous analyses of mortality amenable to health care only focused on high-income countries and faced several methodological challenges. In the present analysis, we use the highly standardised cause of death and risk factor estimates generated through the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to improve and expand the quantification of personal health-care access and quality for 195 countries and territories from 1990 to 2015. METHODS We mapped the most widely used list of causes amenable to personal health care developed by Nolte and McKee to 32 GBD causes. We accounted for variations in cause of death certification and misclassifications through the extensive data standardisation processes and redistribution algorithms developed for GBD. To isolate the effects of personal health-care access and quality, we risk-standardised cause-specific mortality rates for each geography-year by removing the joint effects of local environmental and behavioural risks, and adding back the global levels of risk exposure as estimated for GBD 2015. We employed principal component analysis to create a single, interpretable summary measure-the Healthcare Quality and Access (HAQ) Index-on a scale of 0 to 100. The HAQ Index showed strong convergence validity as compared with other health-system indicators, including health expenditure per capita (r=0·88), an index of 11 universal health coverage interventions (r=0·83), and human resources for health per 1000 (r=0·77). We used free disposal hull analysis with bootstrapping to produce a frontier based on the relationship between the HAQ Index and the Socio-demographic Index (SDI), a measure of overall development consisting of income per capita, average years of education, and total fertility rates. This frontier allowed us to better quantify the maximum levels of personal health-care access and quality achieved across the development spectrum, and pinpoint geographies where gaps between observed and potential levels have narrowed or widened over time. FINDINGS Between 1990 and 2015, nearly all countries and territories saw their HAQ Index values improve; nonetheless, the difference between the highest and lowest observed HAQ Index was larger in 2015 than in 1990, ranging from 28·6 to 94·6. Of 195 geographies, 167 had statistically significant increases in HAQ Index levels since 1990, with South Korea, Turkey, Peru, China, and the Maldives recording among the largest gains by 2015. Performance on the HAQ Index and individual causes showed distinct patterns by region and level of development, yet substantial heterogeneities emerged for several causes, including cancers in highest-SDI countries; chronic kidney disease, diabetes, diarrhoeal diseases, and lower respiratory infections among middle-SDI countries; and measles and tetanus among lowest-SDI countries. While the global HAQ Index average rose from 40·7 (95% uncertainty interval, 39·0-42·8) in 1990 to 53·7 (52·2-55·4) in 2015, far less progress occurred in narrowing the gap between observed HAQ Index values and maximum levels achieved; at the global level, the difference between the observed and frontier HAQ Index only decreased from 21·2 in 1990 to 20·1 in 2015. If every country and territory had achieved the highest observed HAQ Index by their corresponding level of SDI, the global average would have been 73·8 in 2015. Several countries, particularly in eastern and western sub-Saharan Africa, reached HAQ Index values similar to or beyond their development levels, whereas others, namely in southern sub-Saharan Africa, the Middle East, and south Asia, lagged behind what geographies of similar development attained between 1990 and 2015. INTERPRETATION This novel extension of the GBD Study shows the untapped potential for personal health-care access and quality improvement across the development spectrum. Amid substantive advances in personal health care at the national level, heterogeneous patterns for individual causes in given countries or territories suggest that few places have consistently achieved optimal health-care access and quality across health-system functions and therapeutic areas. This is especially evident in middle-SDI countries, many of which have recently undergone or are currently experiencing epidemiological transitions. The HAQ Index, if paired with other measures of health-system characteristics such as intervention coverage, could provide a robust avenue for tracking progress on universal health coverage and identifying local priorities for strengthening personal health-care quality and access throughout the world. FUNDING Bill & Melinda Gates Foundation.
Collapse
|
21
|
Blanchard JJ, Bradshaw KR, Garcia CP, Nasrallah HA, Harvey PD, Casey D, Csoboth CT, Hudson JI, Julian L, Lentz E, Nuechterlein KH, Perkins DO, Skale TG, Snowden LR, Tandon R, Tek C, Velligan D, Vinogradov S, O'Gorman C. Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study. Schizophr Res 2017; 185:137-143. [PMID: 28087270 DOI: 10.1016/j.schres.2017.01.011] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Revised: 01/05/2017] [Accepted: 01/05/2017] [Indexed: 11/28/2022]
Abstract
The current study sought to expand on prior reports of the validity and reliability of the CAINS (CAINS) by examining its performance across diverse non-academic clinical settings as employed by raters not affiliated with the scale's developers and across a longer test-retest follow-up period. The properties of the CAINS were examined within the Management of Schizophrenia in Clinical Practice (MOSAIC) schizophrenia registry. A total of 501 participants with a schizophrenia spectrum diagnosis who were receiving usual care were recruited across 15 national Patient Assessment Centers and evaluated with the CAINS, other negative symptom measures, and assessments of functioning, quality of life and cognition. Temporal stability of negative symptoms was assessed across a 3-month follow-up. Results replicated the two-factor structure of the CAINS reflecting Motivation and Pleasure and expression symptoms. The CAINS scales exhibited high internal consistency and temporal stability. Convergent validity was supported by significant correlations between the CAINS subscales with other negative symptom measures. Additionally, the CAINS was significantly correlated with functioning and quality of life. Discriminant validity was demonstrated by small to moderate associations between the CAINS and positive symptoms, depression, and cognition (and these associations were comparable to those found with other negative symptom scales). Findings suggest that the CAINS is a reliable and valid tool for measuring negative symptoms in schizophrenia across diverse clinical samples and settings.
Collapse
Affiliation(s)
| | | | | | - Henry A Nasrallah
- Saint Louis University, 1438 S. Grand Boulevard, Saint Louis, MO 63104 3, USA
| | - Philip D Harvey
- University of Miami, Miller School of Medicine, 1120 NW 14th Street, Miami, FL 33136, USA
| | - Daniel Casey
- Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA
| | | | - James I Hudson
- Harvard Medical School/McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA
| | - Laura Julian
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Ellen Lentz
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Keith H Nuechterlein
- University of California, Los Angeles, 300 UCLA Medical Plaza, Los Angeles, CA 90095-6968, USA
| | | | - Tracey G Skale
- Greater Cincinnati Behavioral Health Services, 1501 Madison Road, Walnut Hills, OH 45206, USA
| | | | - Rajiv Tandon
- University of Florida, Gainesville, FL 32611, USA
| | - Cenk Tek
- Yale University/Connecticut Mental Health Center, 34 Park Street, New Haven, CT 06519, USA
| | - Dawn Velligan
- University of Texas Health Science Center, 7703 Floyd Curl Dr. San Antonio, San Antonio, TX 78240, USA
| | - Sophia Vinogradov
- University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA 94143, USA; San Francisco Veterans Administration Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
| | - Cedric O'Gorman
- Formerly of Genentech. Currently at Intra-Cellular Therapies, Inc., 430 East 29th Street, New York City, NY 10016, USA
| |
Collapse
|
22
|
Culbertson MS, Herring WO, Holl JW, Casey D. Genetic improvement and dissemination for the global commercial swine industry. Anim Prod Sci 2017. [DOI: 10.1071/an17317] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Commercial swine production has become an increasingly globalised industry, with global meat trade demanding that all regions compete on cost and differentiation of pork products. The utilisation of continually improving genetic populations can be one input that helps maintain, or increases, the competitiveness of an individual producer or regional industry. So as to deliver these improving genetic populations, genetic providers of today must focus on developing and implementing best science that delivers improvement on traits affecting commercial profitability. Providers must also efficiently multiply and disseminate the improved merit to the commercial hog production level. The swine-genetics industry has made considerable progress in driving a faster genetic gain over the past 30 years by systematically combining ever-changing computing power, accurate data capture and emerging genomics information. The combination of these technologies today has resulted in hundreds of thousands of animals being genotyped for tens of thousands of markers, and this information is being combined with extensive phenotypic data to deliver rates of genetic gain nearly double what we were able to achieve 20 years ago. As importantly, this scientific advancement can then be combined with the ability to continue to understand and evaluate emerging traits related to animal robustness, well-being and consumer demand, resulting in the most comprehensive definition of selection targets in the history of modern animal improvement. Finally, managing the dissemination of these genes through boar stud and multiplication systems helps ensure that the commercial level minimises lag and utilises the highest-merit genetics available.
Collapse
|
23
|
Lim SS, Allen K, Bhutta ZA, Dandona L, Forouzanfar MH, Fullman N, Gething PW, Goldberg EM, Hay SI, Holmberg M, Kinfu Y, Kutz MJ, Larson HJ, Liang X, Lopez AD, Lozano R, McNellan CR, Mokdad AH, Mooney MD, Naghavi M, Olsen HE, Pigott DM, Salomon JA, Vos T, Wang H, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulle AM, Abraham B, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NME, Abyu GY, Achoki T, Adebiyi AO, Adedeji IA, Afanvi KA, Afshin A, Agarwal A, Agrawal A, Kiadaliri AA, Ahmadieh H, Ahmed KY, Akanda AS, Akinyemi RO, Akinyemiju TF, Akseer N, Al-Aly Z, Alam K, Alam U, Alasfoor D, AlBuhairan FS, Aldhahri SF, Aldridge RW, Alemu ZA, Ali R, Alkerwi A, Alkhateeb MAB, Alla F, Allebeck P, Allen C, Al-Raddadi R, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzman N, Amare AT, Amberbir A, Amegah AK, Amini H, Ammar W, Amrock SM, Andersen HH, Anderson BO, Anderson GM, Antonio CAT, Anwari P, Ärnlöv J, Artaman A, Asayesh H, Asghar RJ, Atique S, Avokpaho EFGA, Awasthi A, Quintanilla BPA, Azzopardi P, Bacha U, Badawi A, Balakrishnan K, Banerjee A, Barac A, Barber R, Barker-Collo SL, Bärnighausen T, Barrero LH, Barrientos-Gutierrez T, Basu S, Bayou TA, Bazargan-Hejazi S, Beardsley J, Bedi N, Beghi E, Béjot Y, Bell ML, Bello AK, Bennett DA, Bensenor IM, Benzian H, Berhane A, Bernabé E, Bernal OA, Betsu BD, Beyene AS, Bhala N, Bhatt S, Biadgilign S, Bienhoff KA, Bikbov B, Binagwaho A, Bisanzio D, Bjertness E, Blore J, Bourne RRA, Brainin M, Brauer M, Brazinova A, Breitborde NJK, Broday DM, Brugha TS, Buchbinder R, Butt ZA, Cahill LE, Campos-Nonato IR, Campuzano JC, Carabin H, Cárdenas R, Carrero JJ, Carter A, Casey D, Caso V, Castañeda-Orjuela CA, Rivas JC, Catalá-López F, Cavalleri F, Cecílio P, Chang HY, Chang JC, Charlson FJ, Che X, Chen AZ, Chiang PPC, Chibalabala M, Chisumpa VH, Choi JYJ, Chowdhury R, Christensen H, Ciobanu LG, Cirillo M, Coates MM, Coggeshall M, Cohen AJ, Cooke GS, Cooper C, Cooper LT, Cowie BC, Crump JA, Damtew SA, Dandona R, Dargan PI, Neves JD, Davis AC, Davletov K, de Castro EF, De Leo D, Degenhardt L, Del Gobbo LC, Deribe K, Derrett S, Des Jarlais DC, Deshpande A, deVeber GA, Dey S, Dharmaratne SD, Dhillon PK, Ding EL, Dorsey ER, Doyle KE, Driscoll TR, Duan L, Dubey M, Duncan BB, Ebrahimi H, Endries AY, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Fahimi S, Farid TA, Farinha CSES, Faro A, Farvid MS, Farzadfar F, Feigin VL, Felicio MM, Fereshtehnejad SM, Fernandes JG, Fernandes JC, Ferrari AJ, Fischer F, Fitchett JRA, Fitzmaurice C, Foigt N, Foreman K, Fowkes FGR, Franca EB, Franklin RC, Fraser M, Friedman J, Frostad J, Fürst T, Gabbe B, Garcia-Basteiro AL, Gebre T, Gebrehiwot TT, Gebremedhin AT, Gebru AA, Gessner BD, Gillum RF, Ginawi IAM, Giref AZ, Giroud M, Gishu MD, Giussani G, Godwin W, Gona P, Goodridge A, Gopalani SV, Gotay CC, Goto A, Gouda HN, Graetz N, Greenwell KF, Griswold M, Gugnani H, Guo Y, Gupta R, Gupta R, Gupta V, Gutiérrez RA, Gyawali B, Haagsma JA, Haakenstad A, Hafezi-Nejad N, Haile D, Hailu GB, Halasa YA, Hamadeh RR, Hamidi S, Hammami M, Hankey GJ, Harb HL, Haro JM, Hassanvand MS, Havmoeller R, Heredia-Pi IB, Hoek HW, Horino M, Horita N, Hosgood HD, Hoy DG, Htet AS, Hu G, Huang H, Iburg KM, Idrisov BT, Inoue M, Islami F, Jacobs TA, Jacobsen KH, Jahanmehr N, Jakovljevic MB, James P, Jansen HAFM, Javanbakht M, Jayaraman SP, Jayatilleke AU, Jee SH, Jeemon P, Jha V, Jiang Y, Jibat T, Jin Y, Jonas JB, Kabir Z, Kalkonde Y, Kamal R, Kan H, Kandel A, Karch A, Karema CK, Karimkhani C, Karunapema P, Kasaeian A, Kassebaum NJ, Kaul A, Kawakami N, Kayibanda JF, Keiyoro PN, Kemmer L, Kemp AH, Kengne AP, Keren A, Kesavachandran CN, Khader YS, Khan AR, Khan EA, Khan G, Khang YH, Khoja TAM, Khosravi A, Khubchandani J, Kieling C, Kim CI, Kim D, Kim S, Kim YJ, Kimokoti RW, Kissoon N, Kivipelto M, Knibbs LD, Kokubo Y, Kolte D, Kosen S, Kotsakis GA, Koul PA, Koyanagi A, Kravchenko M, Krueger H, Defo BK, Kuchenbecker RS, Kuipers EJ, Kulikoff XR, Kulkarni VS, Kumar GA, Kwan GF, Kyu HH, Lal A, Lal DK, Lalloo R, Lam H, Lan Q, Langan SM, Larsson A, Laryea DO, Latif AA, Leasher JL, Leigh J, Leinsalu M, Leung J, Leung R, Levi M, Li Y, Li Y, Lind M, Linn S, Lipshultz SE, Liu PY, Liu S, Liu Y, Lloyd BK, Lo LT, Logroscino G, Lotufo PA, Lucas RM, Lunevicius R, El Razek MMA, Magis-Rodriguez C, Mahdavi M, Majdan M, Majeed A, Malekzadeh R, Malta DC, Mapoma CC, Margolis DJ, Martin RV, Martinez-Raga J, Masiye F, Mason-Jones AJ, Massano J, Matzopoulos R, Mayosi BM, McGrath JJ, McKee M, Meaney PA, Mehari A, Mekonnen AB, Melaku YA, Memiah P, Memish ZA, Mendoza W, Mensink GBM, Meretoja A, Meretoja TJ, Mesfin YM, Mhimbira FA, Micha R, Miller TR, Mills EJ, Mirarefin M, Misganaw A, Mitchell PB, Mock CN, Mohammadi A, Mohammed S, Monasta L, de la Cruz Monis J, Hernandez JCM, Montico M, Moradi-Lakeh M, Morawska L, Mori R, Mueller UO, Murdoch ME, Murimira B, Murray J, Murthy GVS, Murthy S, Musa KI, Nachega JB, Nagel G, Naidoo KS, Naldi L, Nangia V, Neal B, Nejjari C, Newton CR, Newton JN, Ngalesoni FN, Nguhiu P, Nguyen G, Le Nguyen Q, Nisar MI, Pete PMN, Nolte S, Nomura M, Norheim OF, Norrving B, Obermeyer CM, Ogbo FA, Oh IH, Oladimeji O, Olivares PR, Olusanya BO, Olusanya JO, Opio JN, Oren E, Ortiz A, Osborne RH, Ota E, Owolabi MO, PA M, Park EK, Park HY, Parry CD, Parsaeian M, Patel T, Patel V, Caicedo AJP, Patil ST, Patten SB, Patton GC, Paudel D, Pedro JM, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay JD, Pinho C, Pishgar F, Polinder S, Poulton RG, Pourmalek F, Qorbani M, Rabiee RHS, Radfar A, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajsic S, Raju M, Ram U, Rana SM, Ranabhat CL, Ranganathan K, Rao PC, Refaat AH, Reitsma MB, Remuzzi G, Resnikoff S, Ribeiro AL, Blancas MJR, Roba HS, Roberts B, Rodriguez A, Rojas-Rueda D, Ronfani L, Roshandel G, Roth GA, Rothenbacher D, Roy A, Roy N, Sackey BB, Sagar R, Saleh MM, Sanabria JR, Santos JV, Santomauro DF, Santos IS, Sarmiento-Suarez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Sawyer SM, Schmidhuber J, Schmidt MI, Schneider IJC, Schutte AE, Schwebel DC, Seedat S, Sepanlou SG, Servan-Mori EE, Shackelford K, Shaheen A, Shaikh MA, Levy TS, Sharma R, She J, Sheikhbahaei S, Shen J, Sheth KN, Shey M, Shi P, Shibuya K, Shigematsu M, Shin MJ, Shiri R, Shishani K, Shiue I, Sigfusdottir ID, Silpakit N, Silva DAS, Silverberg JI, Simard EP, Sindi S, Singh A, Singh GM, Singh JA, Singh OP, Singh PK, Skirbekk V, Sligar A, Soneji S, Søreide K, Sorensen RJD, Soriano JB, Soshnikov S, Sposato LA, Sreeramareddy CT, Stahl HC, Stanaway JD, Stathopoulou V, Steckling N, Steel N, Stein DJ, Steiner C, Stöckl H, Stranges S, Strong M, Sun J, Sunguya BF, Sur P, Swaminathan S, Sykes BL, Szoeke CEI, Tabarés-Seisdedos R, Tabb KM, Talongwa RT, Tarawneh MR, Tavakkoli M, Taye B, Taylor HR, Tedla BA, Tefera W, Tegegne TK, Tekle DY, Shifa GT, Terkawi AS, Tessema GA, Thakur JS, Thomson AJ, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tobe-Gai R, Tonelli M, Topor-Madry R, Topouzis F, Tran BX, Truelsen T, Dimbuene ZT, Tura AK, Tuzcu EM, Tyrovolas S, Ukwaja KN, Undurraga EA, Uneke CJ, Uthman OA, van Donkelaar A, Varakin YY, Vasankari T, Vasconcelos AMN, Veerman JL, Venketasubramanian N, Verma RK, Violante FS, Vlassov VV, Volkow P, Vollset SE, Wagner GR, Wallin MT, Wang L, Wanga V, Watkins DA, Weichenthal S, Weiderpass E, Weintraub RG, Weiss DJ, Werdecker A, Westerman R, Whiteford HA, Wilkinson JD, Wiysonge CS, Wolfe CDA, Wolfe I, Won S, Woolf AD, Workie SB, Wubshet M, Xu G, Yadav AK, Yakob B, Yalew AZ, Yan LL, Yano Y, Yaseri M, Ye P, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Zaidi Z, El Sayed Zaki M, Zambrana-Torrelio C, Zapata T, Zegeye EA, Zhao Y, Zhou M, Zodpey S, Zonies D, Murray CJL. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet 2016; 388:1813-1850. [PMID: 27665228 PMCID: PMC5055583 DOI: 10.1016/s0140-6736(16)31467-2] [Citation(s) in RCA: 250] [Impact Index Per Article: 31.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2016] [Revised: 08/13/2016] [Accepted: 08/16/2016] [Indexed: 02/05/2023]
Abstract
BACKGROUND In September, 2015, the UN General Assembly established the Sustainable Development Goals (SDGs). The SDGs specify 17 universal goals, 169 targets, and 230 indicators leading up to 2030. We provide an analysis of 33 health-related SDG indicators based on the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015). METHODS We applied statistical methods to systematically compiled data to estimate the performance of 33 health-related SDG indicators for 188 countries from 1990 to 2015. We rescaled each indicator on a scale from 0 (worst observed value between 1990 and 2015) to 100 (best observed). Indices representing all 33 health-related SDG indicators (health-related SDG index), health-related SDG indicators included in the Millennium Development Goals (MDG index), and health-related indicators not included in the MDGs (non-MDG index) were computed as the geometric mean of the rescaled indicators by SDG target. We used spline regressions to examine the relations between the Socio-demographic Index (SDI, a summary measure based on average income per person, educational attainment, and total fertility rate) and each of the health-related SDG indicators and indices. FINDINGS In 2015, the median health-related SDG index was 59·3 (95% uncertainty interval 56·8-61·8) and varied widely by country, ranging from 85·5 (84·2-86·5) in Iceland to 20·4 (15·4-24·9) in Central African Republic. SDI was a good predictor of the health-related SDG index (r2=0·88) and the MDG index (r2=0·92), whereas the non-MDG index had a weaker relation with SDI (r2=0·79). Between 2000 and 2015, the health-related SDG index improved by a median of 7·9 (IQR 5·0-10·4), and gains on the MDG index (a median change of 10·0 [6·7-13·1]) exceeded that of the non-MDG index (a median change of 5·5 [2·1-8·9]). Since 2000, pronounced progress occurred for indicators such as met need with modern contraception, under-5 mortality, and neonatal mortality, as well as the indicator for universal health coverage tracer interventions. Moderate improvements were found for indicators such as HIV and tuberculosis incidence, minimal changes for hepatitis B incidence took place, and childhood overweight considerably worsened. INTERPRETATION GBD provides an independent, comparable avenue for monitoring progress towards the health-related SDGs. Our analysis not only highlights the importance of income, education, and fertility as drivers of health improvement but also emphasises that investments in these areas alone will not be sufficient. Although considerable progress on the health-related MDG indicators has been made, these gains will need to be sustained and, in many cases, accelerated to achieve the ambitious SDG targets. The minimal improvement in or worsening of health-related indicators beyond the MDGs highlight the need for additional resources to effectively address the expanded scope of the health-related SDGs. FUNDING Bill & Melinda Gates Foundation.
Collapse
|
24
|
Casey D, Jaffer F, Pepito D. Medical image of the week: splenic infarction. Southwest J Pulm Crit Care 2016. [DOI: 10.13175/swjpcc060-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
25
|
Casey D, Brown L, Gajwani R, Islam Z, Jasani R, Parsons H, Tah P, Birchwood M, Singh SP. Predictors of engagement in first-episode psychosis. Schizophr Res 2016; 175:204-208. [PMID: 27132495 DOI: 10.1016/j.schres.2016.04.030] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2015] [Revised: 04/14/2016] [Accepted: 04/18/2016] [Indexed: 11/19/2022]
Abstract
Engagement with psychiatric services is critical for ensuring successful outcomes in patients experiencing a first episode of psychosis (FEP). However, it is not known how sociodemographic factors and patient beliefs about the causes of mental illness affect engagement. This study explored predictors of engagement in a cohort of 103 FEP patients presenting to an early-intervention service. Beliefs that mental illness is caused by social stress or thinking odd thoughts predicted higher engagement scores. Patients with no qualifications were found to have higher engagement scores than those educated to a higher level. Ethnicity, gender, age and socioeconomic factors were not significantly correlated with engagement scores. Duration of untreated illness (DUI) significantly predicted higher engagement scores, but only for values >1220days. Duration of untreated psychosis (DUP) was not a significant predictor of patient engagement scores. Patient beliefs about the causes of mental illness are an important factor to be taken into consideration and may represent a target of interventions to increase engagement in FEP.
Collapse
Affiliation(s)
- Daniel Casey
- James Paget University Hospital, Lowestoft Rd., Gorleston NR31 6LA, UK.
| | - Luke Brown
- Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK
| | - Ruchika Gajwani
- Institute of Health and Wellbeing, University of Glasgow, Glasgow, G3 8SJ
| | - Zoebia Islam
- Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK
| | - Rubina Jasani
- Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK
| | - Helen Parsons
- Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK
| | - Priya Tah
- Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK
| | - Max Birchwood
- Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK
| | - Swaran P Singh
- Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK
| |
Collapse
|
26
|
Eder D, Spears B, Casey D, Pak A, Ma T, Izumi N, Pollock B, Weber C, Kritcher A, Jones O, Milovich J, Town R, Robey H, Hinkel D, Callahan D, Hatchett S, Knauer J, Yeamans C, Bleuel D, Nagel S, Hatarik R, Khan S, Sayre D, Caggiano J, Grim G, Eckart M, Fittinghoff D, Merrill F, Bradley D. Simulations of symcap and layered NIF experiments with top/bottom laser asymmetry to impose P1 drive on capsules. ACTA ACUST UNITED AC 2016. [DOI: 10.1088/1742-6596/717/1/012014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
27
|
Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R, Casey D, Coates MM, Cohen A, Delwiche K, Estep K, Frostad JJ, Astha KC, Kyu HH, Moradi-Lakeh M, Ng M, Slepak EL, Thomas BA, Wagner J, Aasvang GM, Abbafati C, Abbasoglu Ozgoren A, Abd-Allah F, Abera SF, Aboyans V, Abraham B, Abraham JP, Abubakar I, Abu-Rmeileh NME, Aburto TC, Achoki T, Adelekan A, Adofo K, Adou AK, Adsuar JC, Afshin A, Agardh EE, Al Khabouri MJ, Al Lami FH, Alam SS, Alasfoor D, Albittar MI, Alegretti MA, Aleman AV, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Ali MK, Alla F, Allebeck P, Allen PJ, Alsharif U, Alvarez E, Alvis-Guzman N, Amankwaa AA, Amare AT, Ameh EA, Ameli O, Amini H, Ammar W, Anderson BO, Antonio CAT, Anwari P, Argeseanu Cunningham S, Arnlöv J, Arsenijevic VSA, Artaman A, Asghar RJ, Assadi R, Atkins LS, Atkinson C, Avila MA, Awuah B, Badawi A, Bahit MC, Bakfalouni T, Balakrishnan K, Balalla S, Balu RK, Banerjee A, Barber RM, Barker-Collo SL, Barquera S, Barregard L, Barrero LH, Barrientos-Gutierrez T, Basto-Abreu AC, Basu A, Basu S, Basulaiman MO, Batis Ruvalcaba C, Beardsley J, Bedi N, Bekele T, Bell ML, Benjet C, Bennett DA, Benzian H, Bernabé E, Beyene TJ, Bhala N, Bhalla A, Bhutta ZA, Bikbov B, Bin Abdulhak AA, Blore JD, Blyth FM, Bohensky MA, Bora Başara B, Borges G, Bornstein NM, Bose D, Boufous S, Bourne RR, Brainin M, Brazinova A, Breitborde NJ, Brenner H, Briggs ADM, Broday DM, Brooks PM, Bruce NG, Brugha TS, Brunekreef B, Buchbinder R, Bui LN, Bukhman G, Bulloch AG, Burch M, Burney PGJ, Campos-Nonato IR, Campuzano JC, Cantoral AJ, Caravanos J, Cárdenas R, Cardis E, Carpenter DO, Caso V, Castañeda-Orjuela CA, Castro RE, Catalá-López F, Cavalleri F, Çavlin A, Chadha VK, Chang JC, Charlson FJ, Chen H, Chen W, Chen Z, Chiang PP, Chimed-Ochir O, Chowdhury R, Christophi CA, Chuang TW, Chugh SS, Cirillo M, Claßen TKD, Colistro V, Colomar M, Colquhoun SM, Contreras AG, Cooper C, Cooperrider K, Cooper LT, Coresh J, Courville KJ, Criqui MH, Cuevas-Nasu L, Damsere-Derry J, Danawi H, Dandona L, Dandona R, Dargan PI, Davis A, Davitoiu DV, Dayama A, de Castro EF, De la Cruz-Góngora V, De Leo D, de Lima G, Degenhardt L, del Pozo-Cruz B, Dellavalle RP, Deribe K, Derrett S, Des Jarlais DC, Dessalegn M, deVeber GA, Devries KM, Dharmaratne SD, Dherani MK, Dicker D, Ding EL, Dokova K, Dorsey ER, Driscoll TR, Duan L, Durrani AM, Ebel BE, Ellenbogen RG, Elshrek YM, Endres M, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Fahimi S, Faraon EJA, Farzadfar F, Fay DFJ, Feigin VL, Feigl AB, Fereshtehnejad SM, Ferrari AJ, Ferri CP, Flaxman AD, Fleming TD, Foigt N, Foreman KJ, Paleo UF, Franklin RC, Gabbe B, Gaffikin L, Gakidou E, Gamkrelidze A, Gankpé FG, Gansevoort RT, García-Guerra FA, Gasana E, Geleijnse JM, Gessner BD, Gething P, Gibney KB, Gillum RF, Ginawi IAM, Giroud M, Giussani G, Goenka S, Goginashvili K, Gomez Dantes H, Gona P, Gonzalez de Cosio T, González-Castell D, Gotay CC, Goto A, Gouda HN, Guerrant RL, Gugnani HC, Guillemin F, Gunnell D, Gupta R, Gupta R, Gutiérrez RA, Hafezi-Nejad N, Hagan H, Hagstromer M, Halasa YA, Hamadeh RR, Hammami M, Hankey GJ, Hao Y, Harb HL, Haregu TN, Haro JM, Havmoeller R, Hay SI, Hedayati MT, Heredia-Pi IB, Hernandez L, Heuton KR, Heydarpour P, Hijar M, Hoek HW, Hoffman HJ, Hornberger JC, Hosgood HD, Hoy DG, Hsairi M, Hu G, Hu H, Huang C, Huang JJ, Hubbell BJ, Huiart L, Husseini A, Iannarone ML, Iburg KM, Idrisov BT, Ikeda N, Innos K, Inoue M, Islami F, Ismayilova S, Jacobsen KH, Jansen HA, Jarvis DL, Jassal SK, Jauregui A, Jayaraman S, Jeemon P, Jensen PN, Jha V, Jiang F, Jiang G, Jiang Y, Jonas JB, Juel K, Kan H, Kany Roseline SS, Karam NE, Karch A, Karema CK, Karthikeyan G, Kaul A, Kawakami N, Kazi DS, Kemp AH, Kengne AP, Keren A, Khader YS, Khalifa SEAH, Khan EA, Khang YH, Khatibzadeh S, Khonelidze I, Kieling C, Kim D, Kim S, Kim Y, Kimokoti RW, Kinfu Y, Kinge JM, Kissela BM, Kivipelto M, Knibbs LD, Knudsen AK, Kokubo Y, Kose MR, Kosen S, Kraemer A, Kravchenko M, Krishnaswami S, Kromhout H, Ku T, Kuate Defo B, Kucuk Bicer B, Kuipers EJ, Kulkarni C, Kulkarni VS, Kumar GA, Kwan GF, Lai T, Lakshmana Balaji A, Lalloo R, Lallukka T, Lam H, Lan Q, Lansingh VC, Larson HJ, Larsson A, Laryea DO, Lavados PM, Lawrynowicz AE, Leasher JL, Lee JT, Leigh J, Leung R, Levi M, Li Y, Li Y, Liang J, Liang X, Lim SS, Lindsay MP, Lipshultz SE, Liu S, Liu Y, Lloyd BK, Logroscino G, London SJ, Lopez N, Lortet-Tieulent J, Lotufo PA, Lozano R, Lunevicius R, Ma J, Ma S, Machado VMP, MacIntyre MF, Magis-Rodriguez C, Mahdi AA, Majdan M, Malekzadeh R, Mangalam S, Mapoma CC, Marape M, Marcenes W, Margolis DJ, Margono C, Marks GB, Martin RV, Marzan MB, Mashal MT, Masiye F, Mason-Jones AJ, Matsushita K, Matzopoulos R, Mayosi BM, Mazorodze TT, McKay AC, McKee M, McLain A, Meaney PA, Medina C, Mehndiratta MM, Mejia-Rodriguez F, Mekonnen W, Melaku YA, Meltzer M, Memish ZA, Mendoza W, Mensah GA, Meretoja A, Mhimbira FA, Micha R, Miller TR, Mills EJ, Misganaw A, Mishra S, Mohamed Ibrahim N, Mohammad KA, Mokdad AH, Mola GL, Monasta L, Montañez Hernandez JC, Montico M, Moore AR, Morawska L, Mori R, Moschandreas J, Moturi WN, Mozaffarian D, Mueller UO, Mukaigawara M, Mullany EC, Murthy KS, Naghavi M, Nahas Z, Naheed A, Naidoo KS, Naldi L, Nand D, Nangia V, Narayan KMV, Nash D, Neal B, Nejjari C, Neupane SP, Newton CR, Ngalesoni FN, Ngirabega JDD, Nguyen G, Nguyen NT, Nieuwenhuijsen MJ, Nisar MI, Nogueira JR, Nolla JM, Nolte S, Norheim OF, Norman RE, Norrving B, Nyakarahuka L, Oh IH, Ohkubo T, Olusanya BO, Omer SB, Opio JN, Orozco R, Pagcatipunan RS, Pain AW, Pandian JD, Panelo CIA, Papachristou C, Park EK, Parry CD, Paternina Caicedo AJ, Patten SB, Paul VK, Pavlin BI, Pearce N, Pedraza LS, Pedroza A, Pejin Stokic L, Pekericli A, Pereira DM, Perez-Padilla R, Perez-Ruiz F, Perico N, Perry SAL, Pervaiz A, Pesudovs K, Peterson CB, Petzold M, Phillips MR, Phua HP, Plass D, Poenaru D, Polanczyk GV, Polinder S, Pond CD, Pope CA, Pope D, Popova S, Pourmalek F, Powles J, Prabhakaran D, Prasad NM, Qato DM, Quezada AD, Quistberg DAA, Racapé L, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman SU, Raju M, Rakovac I, Rana SM, Rao M, Razavi H, Reddy KS, Refaat AH, Rehm J, Remuzzi G, Ribeiro AL, Riccio PM, Richardson L, Riederer A, Robinson M, Roca A, Rodriguez A, Rojas-Rueda D, Romieu I, Ronfani L, Room R, Roy N, Ruhago GM, Rushton L, Sabin N, Sacco RL, Saha S, Sahathevan R, Sahraian MA, Salomon JA, Salvo D, Sampson UK, Sanabria JR, Sanchez LM, Sánchez-Pimienta TG, Sanchez-Riera L, Sandar L, Santos IS, Sapkota A, Satpathy M, Saunders JE, Sawhney M, Saylan MI, Scarborough P, Schmidt JC, Schneider IJC, Schöttker B, Schwebel DC, Scott JG, Seedat S, Sepanlou SG, Serdar B, Servan-Mori EE, Shaddick G, Shahraz S, Levy TS, Shangguan S, She J, Sheikhbahaei S, Shibuya K, Shin HH, Shinohara Y, Shiri R, Shishani K, Shiue I, Sigfusdottir ID, Silberberg DH, Simard EP, Sindi S, Singh A, Singh GM, Singh JA, Skirbekk V, Sliwa K, Soljak M, Soneji S, Søreide K, Soshnikov S, Sposato LA, Sreeramareddy CT, Stapelberg NJC, Stathopoulou V, Steckling N, Stein DJ, Stein MB, Stephens N, Stöckl H, Straif K, Stroumpoulis K, Sturua L, Sunguya BF, Swaminathan S, Swaroop M, Sykes BL, Tabb KM, Takahashi K, Talongwa RT, Tandon N, Tanne D, Tanner M, Tavakkoli M, Te Ao BJ, Teixeira CM, Téllez Rojo MM, Terkawi AS, Texcalac-Sangrador JL, Thackway SV, Thomson B, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tobollik M, Tonelli M, Topouzis F, Towbin JA, Toyoshima H, Traebert J, Tran BX, Trasande L, Trillini M, Trujillo U, Dimbuene ZT, Tsilimbaris M, Tuzcu EM, Uchendu US, Ukwaja KN, Uzun SB, van de Vijver S, Van Dingenen R, van Gool CH, van Os J, Varakin YY, Vasankari TJ, Vasconcelos AMN, Vavilala MS, Veerman LJ, Velasquez-Melendez G, Venketasubramanian N, Vijayakumar L, Villalpando S, Violante FS, Vlassov VV, Vollset SE, Wagner GR, Waller SG, Wallin MT, Wan X, Wang H, Wang J, Wang L, Wang W, Wang Y, Warouw TS, Watts CH, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Wessells KR, Westerman R, Whiteford HA, Wilkinson JD, Williams HC, Williams TN, Woldeyohannes SM, Wolfe CDA, Wong JQ, Woolf AD, Wright JL, Wurtz B, Xu G, Yan LL, Yang G, Yano Y, Ye P, Yenesew M, Yentür GK, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Younoussi Z, Yu C, Zaki ME, Zhao Y, Zheng Y, Zhou M, Zhu J, Zhu S, Zou X, Zunt JR, Lopez AD, Vos T, Murray CJ. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386:2287-323. [PMID: 26364544 PMCID: PMC4685753 DOI: 10.1016/s0140-6736(15)00128-2] [Citation(s) in RCA: 1715] [Impact Index Per Article: 190.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. METHODS Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2010 methods. Risk-outcome pairs meeting explicit evidence criteria were assessed for 188 countries for the period 1990-2013 by age and sex using three inputs: risk exposure, relative risks, and the theoretical minimum risk exposure level (TMREL). Risks are organised into a hierarchy with blocks of behavioural, environmental and occupational, and metabolic risks at the first level of the hierarchy. The next level in the hierarchy includes nine clusters of related risks and two individual risks, with more detail provided at levels 3 and 4 of the hierarchy. Compared with GBD 2010, six new risk factors have been added: handwashing practices, occupational exposure to trichloroethylene, childhood wasting, childhood stunting, unsafe sex, and low glomerular filtration rate. For most risks, data for exposure were synthesised with a Bayesian meta-regression method, DisMod-MR 2.0, or spatial-temporal Gaussian process regression. Relative risks were based on meta-regressions of published cohort and intervention studies. Attributable burden for clusters of risks and all risks combined took into account evidence on the mediation of some risks such as high body-mass index (BMI) through other risks such as high systolic blood pressure and high cholesterol. FINDINGS All risks combined account for 57·2% (95% uncertainty interval [UI] 55·8-58·5) of deaths and 41·6% (40·1-43·0) of DALYs. Risks quantified account for 87·9% (86·5-89·3) of cardiovascular disease DALYs, ranging to a low of 0% for neonatal disorders and neglected tropical diseases and malaria. In terms of global DALYs in 2013, six risks or clusters of risks each caused more than 5% of DALYs: dietary risks accounting for 11·3 million deaths and 241·4 million DALYs, high systolic blood pressure for 10·4 million deaths and 208·1 million DALYs, child and maternal malnutrition for 1·7 million deaths and 176·9 million DALYs, tobacco smoke for 6·1 million deaths and 143·5 million DALYs, air pollution for 5·5 million deaths and 141·5 million DALYs, and high BMI for 4·4 million deaths and 134·0 million DALYs. Risk factor patterns vary across regions and countries and with time. In sub-Saharan Africa, the leading risk factors are child and maternal malnutrition, unsafe sex, and unsafe water, sanitation, and handwashing. In women, in nearly all countries in the Americas, north Africa, and the Middle East, and in many other high-income countries, high BMI is the leading risk factor, with high systolic blood pressure as the leading risk in most of Central and Eastern Europe and south and east Asia. For men, high systolic blood pressure or tobacco use are the leading risks in nearly all high-income countries, in north Africa and the Middle East, Europe, and Asia. For men and women, unsafe sex is the leading risk in a corridor from Kenya to South Africa. INTERPRETATION Behavioural, environmental and occupational, and metabolic risks can explain half of global mortality and more than one-third of global DALYs providing many opportunities for prevention. Of the larger risks, the attributable burden of high BMI has increased in the past 23 years. In view of the prominence of behavioural risk factors, behavioural and social science research on interventions for these risks should be strengthened. Many prevention and primary care policy options are available now to act on key risks. FUNDING Bill & Melinda Gates Foundation.
Collapse
|
28
|
Newton JN, Briggs ADM, Murray CJL, Dicker D, Foreman KJ, Wang H, Naghavi M, Forouzanfar MH, Ohno SL, Barber RM, Vos T, Stanaway JD, Schmidt JC, Hughes AJ, Fay DFJ, Ecob R, Gresser C, McKee M, Rutter H, Abubakar I, Ali R, Anderson HR, Banerjee A, Bennett DA, Bernabé E, Bhui KS, Biryukov SM, Bourne RR, Brayne CEG, Bruce NG, Brugha TS, Burch M, Capewell S, Casey D, Chowdhury R, Coates MM, Cooper C, Critchley JA, Dargan PI, Dherani MK, Elliott P, Ezzati M, Fenton KA, Fraser MS, Fürst T, Greaves F, Green MA, Gunnell DJ, Hannigan BM, Hay RJ, Hay SI, Hemingway H, Larson HJ, Looker KJ, Lunevicius R, Lyons RA, Marcenes W, Mason-Jones AJ, Matthews FE, Moller H, Murdoch ME, Newton CR, Pearce N, Piel FB, Pope D, Rahimi K, Rodriguez A, Scarborough P, Schumacher AE, Shiue I, Smeeth L, Tedstone A, Valabhji J, Williams HC, Wolfe CDA, Woolf AD, Davis ACJ. Changes in health in England, with analysis by English regions and areas of deprivation, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386:2257-74. [PMID: 26382241 PMCID: PMC4672153 DOI: 10.1016/s0140-6736(15)00195-6] [Citation(s) in RCA: 261] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND In the Global Burden of Disease Study 2013 (GBD 2013), knowledge about health and its determinants has been integrated into a comparable framework to inform health policy. Outputs of this analysis are relevant to current policy questions in England and elsewhere, particularly on health inequalities. We use GBD 2013 data on mortality and causes of death, and disease and injury incidence and prevalence to analyse the burden of disease and injury in England as a whole, in English regions, and within each English region by deprivation quintile. We also assess disease and injury burden in England attributable to potentially preventable risk factors. England and the English regions are compared with the remaining constituent countries of the UK and with comparable countries in the European Union (EU) and beyond. METHODS We extracted data from the GBD 2013 to compare mortality, causes of death, years of life lost (YLLs), years lived with a disability (YLDs), and disability-adjusted life-years (DALYs) in England, the UK, and 18 other countries (the first 15 EU members [apart from the UK] and Australia, Canada, Norway, and the USA [EU15+]). We extended elements of the analysis to English regions, and subregional areas defined by deprivation quintile (deprivation areas). We used data split by the nine English regions (corresponding to the European boundaries of the Nomenclature for Territorial Statistics level 1 [NUTS 1] regions), and by quintile groups within each English region according to deprivation, thereby making 45 regional deprivation areas. Deprivation quintiles were defined by area of residence ranked at national level by Index of Multiple Deprivation score, 2010. Burden due to various risk factors is described for England using new GBD methodology to estimate independent and overlapping attributable risk for five tiers of behavioural, metabolic, and environmental risk factors. We present results for 306 causes and 2337 sequelae, and 79 risks or risk clusters. FINDINGS Between 1990 and 2013, life expectancy from birth in England increased by 5·4 years (95% uncertainty interval 5·0-5·8) from 75·9 years (75·9-76·0) to 81·3 years (80·9-81·7); gains were greater for men than for women. Rates of age-standardised YLLs reduced by 41·1% (38·3-43·6), whereas DALYs were reduced by 23·8% (20·9-27·1), and YLDs by 1·4% (0·1-2·8). For these measures, England ranked better than the UK and the EU15+ means. Between 1990 and 2013, the range in life expectancy among 45 regional deprivation areas remained 8·2 years for men and decreased from 7·2 years in 1990 to 6·9 years in 2013 for women. In 2013, the leading cause of YLLs was ischaemic heart disease, and the leading cause of DALYs was low back and neck pain. Known risk factors accounted for 39·6% (37·7-41·7) of DALYs; leading behavioural risk factors were suboptimal diet (10·8% [9·1-12·7]) and tobacco (10·7% [9·4-12·0]). INTERPRETATION Health in England is improving although substantial opportunities exist for further reductions in the burden of preventable disease. The gap in mortality rates between men and women has reduced, but marked health inequalities between the least deprived and most deprived areas remain. Declines in mortality have not been matched by similar declines in morbidity, resulting in people living longer with diseases. Health policies must therefore address the causes of ill health as well as those of premature mortality. Systematic action locally and nationally is needed to reduce risk exposures, support healthy behaviours, alleviate the severity of chronic disabling disorders, and mitigate the effects of socioeconomic deprivation. FUNDING Bill & Melinda Gates Foundation and Public Health England.
Collapse
Affiliation(s)
- John N Newton
- Public Health England, London, UK; University of Manchester, Manchester, UK.
| | | | | | - Daniel Dicker
- Institute for Health Metrics and Evaluation, Seattle, WA, USA
| | - Kyle J Foreman
- Institute for Health Metrics and Evaluation, Seattle, WA, USA
| | - Haidong Wang
- Institute for Health Metrics and Evaluation, Seattle, WA, USA
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, Seattle, WA, USA
| | | | | | - Ryan M Barber
- Institute for Health Metrics and Evaluation, Seattle, WA, USA
| | - Theo Vos
- Institute for Health Metrics and Evaluation, Seattle, WA, USA
| | | | | | | | | | | | | | - Martin McKee
- Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK
| | - Harry Rutter
- London School of Hygiene & Tropical Medicine, Oxford Martin School, University of Oxford, Oxford, UK
| | - Ibrahim Abubakar
- Public Health England, London, UK; Centre for Infectious Disease Epidemiology and MRC Clinical Trials Unit, London, UK
| | - Raghib Ali
- INDOX Cancer Research Network, Oxford, UK; John Radcliffe Hospital, Oxford, UK; Green-Templeton College, University of Oxford, Oxford, UK
| | - H Ross Anderson
- Population Health Research Institute, Hamilton, ON, Canada; MRC-PHE Centre for Environment and Health, London, UK; St George's, University of London, London, UK
| | | | - Derrick A Bennett
- Clinical Trials Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | | | - Kamaldeep S Bhui
- Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine, Queen Mary University of London, London, UK
| | | | - Rupert R Bourne
- Vision & Eye Research Unit, Anglia Ruskin University, Cambridge, UK
| | - Carol E G Brayne
- Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK
| | | | | | - Michael Burch
- Great Ormond Street Hospital for Children, London, UK
| | | | - Daniel Casey
- Institute for Health Metrics and Evaluation, Seattle, WA, USA
| | | | | | - Cyrus Cooper
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southhampton, UK
| | | | - Paul I Dargan
- Guy's and St Thomas' NHS Foundation Trust, London, UK
| | | | - Paul Elliott
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, Imperial College London, London, UK
| | - Majid Ezzati
- MRC-PHE Centre for Population Health, School of Public Health, Imperial College London, London, UK
| | | | - Maya S Fraser
- Institute for Health Metrics and Evaluation, Seattle, WA, USA
| | - Thomas Fürst
- Department of Infectious Disease Epidemiology, Imperial College London, London, UK
| | - Felix Greaves
- Public Health England, London, UK; Department of Primary Care and Public Health, Imperial College London, London, UK
| | - Mark A Green
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - David J Gunnell
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | | | | | - Simon I Hay
- Institute for Health Metrics and Evaluation, Seattle, WA, USA; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - Harry Hemingway
- University College London, London, UK; Farr Institute of Health Informatics Research, London, UK
| | - Heidi J Larson
- Institute for Health Metrics and Evaluation, Seattle, WA, USA; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
| | - Katharine J Looker
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Raimundas Lunevicius
- University of Liverpool, Liverpool, UK; Aintree University Hospital NHS Foundation Trust, University of Liverpool, Liverpool, UK
| | - Ronan A Lyons
- Farr Institute, College of Medicine, Swansea University, Swansea, UK
| | | | - Amanda J Mason-Jones
- Department of Health Sciences, University of York, York, UK; Adolescent Health Research Unit, University of Cape Town, Cape Town, South Africa
| | - Fiona E Matthews
- Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK; Institute of Health and Society, Newcastle University, Newcastle, UK
| | - Henrik Moller
- Cancer Epidemiology and Population Health, King's College London, London, UK
| | | | | | - Neil Pearce
- London School of Hygiene & Tropical Medicine, Oxford Martin School, University of Oxford, Oxford, UK
| | | | | | - Kazem Rahimi
- George Institute for Global Health and Division of Cardiovascular Medicine, Oxford Martin School, University of Oxford, Oxford, UK
| | - Alina Rodriguez
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Mid Sweden University, Sundsvall, Sweden
| | - Peter Scarborough
- British Heart Foundation Centre on Population Approaches for NCD Prevention, University of Oxford, Oxford, UK
| | | | - Ivy Shiue
- University of Edinburgh, Edinburgh, Scotland; Northumbria University, Newcastle upon Tyne
| | - Liam Smeeth
- Farr Institute of Health Informatics Research, London, UK; London School of Hygiene & Tropical Medicine, Oxford Martin School, University of Oxford, Oxford, UK
| | | | - Jonathan Valabhji
- NHS England, Leeds, UK; Imperial College Healthcare NHS Trust, London, UK; Imperial College London, London, UK
| | | | | | | | - Adrian C J Davis
- Public Health England, London, UK; London School of Economics, London, UK; University College London, London, UK
| |
Collapse
|
29
|
Casey D. Key strategic factors for stakeholders in the current global biosimilar market. Drug Discov Today 2015; 21:208-11. [PMID: 26375407 DOI: 10.1016/j.drudis.2015.09.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Revised: 08/12/2015] [Accepted: 09/08/2015] [Indexed: 11/16/2022]
Abstract
What are the strategies of success in the global biosimilar market? In general, originators have short-term options available, such as patent litigation, but should focus on sustainable long-term strategies such as development of biobetters or incorporating biosimilars as complements to existing products. For new entrants to the market, the learning curve will be steep and only biosimilars developed to compete with the best-selling biologics will be successful over the next decade. The attitudes of physicians, patients and payers will be crucial to the reception future biosimilars will receive and it will be essential that other players contribute to this debate.
Collapse
Affiliation(s)
- Daniel Casey
- Medical Sciences Division, University of Oxford, OX1 4JD, UK.
| |
Collapse
|
30
|
Nasrallah HA, Harvey PD, Casey D, Csoboth CT, Hudson JI, Julian L, Lentz E, Nuechterlein KH, Perkins DO, Kotowsky N, Skale TG, Snowden LR, Tandon R, Tek C, Velligan D, Vinogradov S, O'Gorman C. The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: a focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. Schizophr Res 2015; 166:69-79. [PMID: 26027848 DOI: 10.1016/j.schres.2015.04.031] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2015] [Revised: 04/09/2015] [Accepted: 04/22/2015] [Indexed: 11/19/2022]
Abstract
BACKGROUND The Management of Schizophrenia in Clinical Practice (MOSAIC), a disease-based registry of schizophrenia, was initiated in December 2012 to address important gaps in our understanding of the impact and burden of schizophrenia and to provide insight into the current status of schizophrenia care in the US. Recruitment began in December 2012 with ongoing assessment continuing through May 2014. METHODS Participants were recruited from a network of 15 centralized Patient Assessment Centers supporting proximal care sites. Broad entry criteria included patients diagnosed with schizophrenia, schizophreniform or schizoaffective disorder, presenting within the normal course of care, in usual treatment settings, aged ≥18years and able to read and speak English. RESULTS By May 2014, 550 participants (65.8% male, 59.8% White, 64.4% single, mean age 42.9years), were enrolled. The majority had a diagnosis of schizophrenia (62.0%). Mean illness duration at entry was 15.0years. Common comorbidities at entry were high lipid levels (26.9%), hypertension (23.1%) and type II diabetes (13%). Participants were categorized by baseline overall Clinical Global Impression-Schizophrenia Severity Score as minimally (9.1%), mildly (25.3%), moderately (39.9%), markedly (22.3%) and severely (3.4%) ill. Most commonly used second generation antipsychotics at entry were risperidone (17.8%), clozapine (16.5%), olanzapine (14.0%), aripiprazole (13.6%) and quetiapine (5.6%). CONCLUSIONS No large-scale patient registry has been conducted in the US to longitudinally follow patients with schizophrenia and describe symptom attributes, support network, care access and disease burden. These data provide important epidemiological, clinical and outcome insights into the burden of schizophrenia in the US.
Collapse
Affiliation(s)
- Henry A Nasrallah
- Saint Louis University, 1438 South Grand Boulevard, Saint Louis, MO 63104, USA.
| | - Philip D Harvey
- University of Miami, 1120 NW 14th Street, Miami, FL 33136, USA
| | - Daniel Casey
- Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA
| | | | - James I Hudson
- Harvard Medical School McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA
| | - Laura Julian
- Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Ellen Lentz
- Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | | | | | | | - Tracey G Skale
- Greater Cincinnati Behavioral Health Services, 1501 Madison Road, Walnut Hills, OH 45206, USA
| | | | - Rajiv Tandon
- University of Florida, Gainesville, FL 32611, USA
| | - Cenk Tek
- Yale University/Connecticut Mental Health Center, 34 Park Street, New Haven, CT 06519, USA
| | - Dawn Velligan
- University of Texas, San Antonio, 1 UTSA Circle, San Antonio, TX 78249, USA
| | - Sophia Vinogradov
- University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA 94143, USA
| | | |
Collapse
|
31
|
Chao E, Lucas D, Beneke M, Casey D, Henderson D, Homp J, Kammeyer T, Lai S, Mauer C, O'Connell R, Schnarr E. SU-F-BRB-06: Validation of Dose Calculation for Helical Tomotherapy with a Rigidly Moving Object. Med Phys 2015. [DOI: 10.1118/1.4925201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
32
|
Florek R, Lang E, Beary D, Tanenbaum R, Casey D, Gomez J. Celiac artery compression syndrome: review of causes and appearances. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2014.12.436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
33
|
Kim Y, Herrmann HW, Jorgenson HJ, Barlow DB, Young CS, Stoeffl W, Casey D, Clancy T, Lopez FE, Oertel JA, Hilsabeck T, Moy K, Batha SH. Conceptual design of the gamma-to-electron magnetic spectrometer for the National Ignition Facility. Rev Sci Instrum 2014; 85:11E122. [PMID: 25430301 DOI: 10.1063/1.4892900] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The Gamma-to-Electron Magnetic Spectrometer (GEMS) diagnostic is designed to measure the prompt γ-ray energy spectrum during high yield deuterium-tritium (DT) implosions at the National Ignition Facility (NIF). The prompt γ-ray spectrum will provide "burn-averaged" observables, including total DT fusion yield, total areal density (ρR), ablator ρR, and fuel ρR. These burn-averaged observables are unique because they are essentially averaged over 4π, providing a global reference for the line-of-sight-specific measurements typical of x-ray and neutron diagnostics. The GEMS conceptual design meets the physics-based requirements: ΔE/E = 3%-5% can be achieved in the range of 2-25 MeV γ-ray energy. Minimum DT neutron yields required for 15% measurement uncertainty at low-resolution mode are: 5 × 10(14) DT-n for ablator ρR (at 0.2 g/cm(2)); 2 × 10(15) DT-n for total DT yield (at 4.2 × 10(-5) γ/n); and 1 × 10(16) DT-n for fuel ρR (at 1 g/cm(2)).
Collapse
Affiliation(s)
- Y Kim
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - H W Herrmann
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - H J Jorgenson
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - D B Barlow
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - C S Young
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - W Stoeffl
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Casey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Clancy
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - F E Lopez
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J A Oertel
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - T Hilsabeck
- General Atomics, San Diego, California 92186, USA
| | - K Moy
- National Security Technologies, Special Technologies Laboratory, Santa Barbara, California 93111, USA
| | - S H Batha
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| |
Collapse
|
34
|
el-Guebaly NA, Hodgins D, Williams R, Schopflocher D, Smith G, Casey D. SY17-1 * HIGHLIGHTS FROM THE CANADIAN LONGITUDINAL STUDIES ON PROBLEM GAMBLING. Alcohol Alcohol 2014. [DOI: 10.1093/alcalc/agu052.72] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Le Pape S, Divol L, Berzak Hopkins L, Mackinnon A, Meezan NB, Casey D, Frenje J, Herrmann H, McNaney J, Ma T, Widmann K, Pak A, Grimm G, Knauer J, Petrasso R, Zylstra A, Rinderknecht H, Rosenberg M, Gatu-Johnson M, Kilkenny JD. Observation of a reflected shock in an indirectly driven spherical implosion at the national ignition facility. Phys Rev Lett 2014; 112:225002. [PMID: 24949774 DOI: 10.1103/physrevlett.112.225002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Indexed: 06/03/2023]
Abstract
A 200 μm radius hot spot at more than 2 keV temperature, 1 g/cm^{3} density has been achieved on the National Ignition Facility using a near vacuum hohlraum. The implosion exhibits ideal one-dimensional behavior and 99% laser-to-hohlraum coupling. The low opacity of the remaining shell at bang time allows for a measurement of the x-ray emission of the reflected central shock in a deuterium plasma. Comparison with 1D hydrodynamic simulations puts constraints on electron-ion collisions and heat conduction. Results are consistent with classical (Spitzer-Harm) heat flux.
Collapse
Affiliation(s)
- S Le Pape
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L Divol
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L Berzak Hopkins
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Mackinnon
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - N B Meezan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Casey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Frenje
- Plasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - H Herrmann
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J McNaney
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Ma
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Widmann
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Pak
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - G Grimm
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J Knauer
- Laboratory for Laser Energetics, University of Rochester, 250 East River Road, Rochester, New York 14623, USA
| | - R Petrasso
- Plasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Zylstra
- Plasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - H Rinderknecht
- Plasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M Rosenberg
- Plasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M Gatu-Johnson
- Plasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J D Kilkenny
- General Atomics Corporation, La Jolla, California 92121, USA
| |
Collapse
|
36
|
Haga A, Nakagawa K, Maurer C, Ruchala K, Chao E, Casey D, Ida S, Sakata D, Magome T, Nakano M, Masutani Y. SU-E-J-203: Reconstruction of the Treatment Area by Use of Sinogram in Helical Tomotherapy. Med Phys 2014. [DOI: 10.1118/1.4888256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
37
|
Robbins CE, Casey D, Bono JV, Murphy SB, Talmo CT, Ward DM. A multidisciplinary total hip arthroplasty protocol with accelerated postoperative rehabilitation: does the patient benefit? Am J Orthop (Belle Mead NJ) 2014; 43:178-181. [PMID: 24730003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Since its debut over 10 years ago, minimally invasive total hip arthroplasty (THA) has often been associated with accelerated postoperative rehabilitation when compared with THA performed with a traditional surgical approach. The objective of this study was to investigate the effect of accelerated postoperative rehabilitation and early mobilization on length of stay and hospital readmissions in patients undergoing THA at one institution. We retrospectively reviewed a consecutive series of 590 patients who underwent THA between January 31, 2011 and April 30, 2011. Six arthroplasty surgeons using varying surgical techniques participated. One hundred ninety patients received accelerated rehabilitation and were mobilized on the day of surgery. The remaining 400 patients were mobilized on postoperative day one (POD1). Length of stay for the accelerated rehabilitation group was 2.06 days and 3.38 days for the standard group. One patient was readmitted to the hospital within 30 days (.52%) in the accelerated group compared to 19 re-hospitalizations (4.72%) in the POD1 group. Ninety-six percent of the accelerated group were discharged home versus 62% in POD1 group. Our results support the use of an accelerated rehabilitation protocol at one institution following total hip replacement surgery.
Collapse
Affiliation(s)
- Claire E Robbins
- Department of Orthopedics, New England Baptist Hospital, Boston, MA.
| | | | | | | | | | | |
Collapse
|
38
|
|
39
|
Casey D, Herscowitz R, Gross R. Pulmonary Langerhans Cell Histiocytosis Presenting as Rapidly Progressive Pulmonary Nodules. Chest 2011. [DOI: 10.1378/chest.1119628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
40
|
Casey D, Oermann E, Chen V, Vahdat S, Suy S, Yu X, Collins S, Subramaniam D, Banovac F, Collins B, Anderson E. Pulmonary Function Tests One Year Following Robotic Radiosurgery for High-Risk Surgical Patients With Stage I Non-small Cell Lung Cancer. Chest 2011. [DOI: 10.1378/chest.1117503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
41
|
Casey D, De Civita M, Dasgupta K. Understanding physical activity facilitators and barriers during and following a supervised exercise programme in Type 2 diabetes: a qualitative study. Diabet Med 2010; 27:79-84. [PMID: 20121893 DOI: 10.1111/j.1464-5491.2009.02873.x] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIMS To assess barriers and facilitators of participation in a supervised exercise programme, and adherence to exercise after programme completion. METHODS Focus group discussions addressed factors which could facilitate attendance, current engagement in exercise, reasons for continuing or discontinuing regular exercise and ways to integrate exercise into daily life. Three focus groups, with a total of 16 participants, were led by a trained moderator; audiotapes were transcribed verbatim; transcripts were coded and themes were identified. Themes that recurred across all three focus groups were considered to have achieved saturation. RESULTS Motivation was the most critical factor in exercising both during and following the programme. Participants appreciated the monitoring, encouragement and accountability provided by programme staff. They voiced a need for better transition to post-programme realities of less support and supervision. Co-morbid conditions were apt to derail them from a regular exercise routine. They viewed the optimal programme as having even greater scheduling flexibility and being closer to them geographically. Post-programme, walking emerged as the most frequent form of physical activity. CONCLUSIONS Adults with Type 2 diabetes require long-term monitoring and support for physical activity and exercise.
Collapse
Affiliation(s)
- D Casey
- Department of Medicine, McGill University, Montréal, QC, Canada
| | | | | |
Collapse
|
42
|
Casey D, De Civita M, Dasgupta K. sustained monitoring and support critical to improving exercise behaviour in type 2 diabetes. Can J Diabetes 2009. [DOI: 10.1016/s1499-2671(09)33229-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
43
|
Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33:957-70. [PMID: 17637610 PMCID: PMC2553721 DOI: 10.1038/sj.npp.1301492] [Citation(s) in RCA: 218] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
In elderly persons, antipsychotic drugs are clinically prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications (schizophrenia and bipolar disorder). The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia. In April 2005, the FDA, based on a meta-analysis of 17 double-blind randomized placebo-controlled trials among elderly people with dementia, determined that atypical antipsychotics were associated with a significantly (1.6-1.7 times) greater mortality risk compared with placebo, and asked that drug manufacturers add a 'black box' warning to prescribing information for these drugs. Most deaths were due to either cardiac or infectious causes, the two most common immediate causes of death in dementia in general. Clinicians, patients, and caregivers are left with unclear choices of treatment for dementia patients with psychosis and/or severe agitation. Not only are psychosis and agitation common in persons with dementia but they also frequently cause considerable caregiver distress and hasten institutionalization of patients. At the same time, there is a paucity of evidence-based treatment alternatives to antipsychotics for this population. Thus, there is insufficient evidence to suggest that psychotropics other than antipsychotics represent an overall effective and safe, let alone better, treatment choice for psychosis or agitation in dementia; currently no such treatment has been approved by the FDA for these symptoms. Similarly, the data on the efficacy of specific psychosocial treatments in patients with dementia are limited and inconclusive. The goal of this White Paper is to review relevant issues and make clinical and research recommendations regarding the treatment of elderly dementia patients with psychosis and/or agitation. The role of shared decision making and caution in using pharmacotherapy for these patients is stressed.
Collapse
Affiliation(s)
- Dilip V Jeste
- Department of Psychiatry and Neurosciences, University of California, San Diego, CA 92161, USA.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Thomas DR, McCarroll L, Roberts R, Karunaratne P, Roberts C, Casey D, Morgan S, Touhig K, Morgan J, Collins F, Hemingway J. Surveillance of insecticide resistance in head lice using biochemical and molecular methods. Arch Dis Child 2006; 91:777-8. [PMID: 16774979 PMCID: PMC2082909 DOI: 10.1136/adc.2005.091280] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Treatment of head louse infection is primarily through topical insecticides. However, there is growing evidence of resistance. A representative population sample was tested using biochemical and molecular methods; it was shown that, in Wales, treatments containing pyrethroids are likely to be less effective in controlling head louse infection than those containing organophosphates.
Collapse
Affiliation(s)
- D Rh Thomas
- National Public Health Service for Wales Communicable Disease Surveillance Centre, Cardiff, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Badaud F, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, Martins CDO, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gay P, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Gris P, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Houben P, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Makovec N, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sumowidagdo S, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Measurement of dijet azimuthal decorrelations at central rapidities in pp collisions at sqrt s =1.96 TeV. Phys Rev Lett 2005; 94:221801. [PMID: 16090381 DOI: 10.1103/physrevlett.94.221801] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2004] [Indexed: 05/03/2023]
Abstract
Correlations in the azimuthal angle between the two largest transverse momentum jets have been measured using the D0 detector in p (-)p collisions at a center-of-mass energy sqrt[s]=1.96 TeV. The analysis is based on an inclusive dijet event sample in the central rapidity region corresponding to an integrated luminosity of 150 pb(-1). Azimuthal correlations are stronger at larger transverse momenta. These are well described in perturbative QCD at next-to-leading order in the strong coupling constant, except at large azimuthal differences where contributions with low transverse momentum are significant.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouchner A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Search for supersymmetry with gauge-mediated breaking in diphoton events at D0. Phys Rev Lett 2005; 94:041801. [PMID: 15783547 DOI: 10.1103/physrevlett.94.041801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2004] [Indexed: 05/24/2023]
Abstract
We report the results of a search for supersymmetry (SUSY) with gauge-mediated breaking in the missing transverse energy distribution of inclusive diphoton events using 263 pb(-1) of data collected by the D0 experiment at the Fermilab Tevatron Collider in 2002-2004. No excess is observed above the background expected from standard model processes, and lower limits on the masses of the lightest neutralino and chargino of about 108 and 195 GeV, respectively, are set at the 95% confidence level. These are the most stringent limits to date for models with gauge-mediated SUSY breaking with a short-lived neutralino as the next-to-lightest SUSY particle.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Badaud F, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gay P, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Gris P, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Houben P, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Makovec N, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sumowidagdo S, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Von Vlimant JR, Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Measurement of the B0s lifetime in the exclusive decay channel B0s-->J/psiphi. Phys Rev Lett 2005; 94:042001. [PMID: 15783550 DOI: 10.1103/physrevlett.94.042001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2004] [Indexed: 05/24/2023]
Abstract
Using the exclusive decay B0s-->J/psi(mu+mu-)phi(K+K-), we report the most precise single measurement of the B0s lifetime. The data sample corresponds to an integrated luminosity of approximately 220 pb(-1) collected with the D0 detector at the Fermilab Tevatron Collider in 2002-2004. We reconstruct 337 signal candidates, from which we extract the B0s lifetime, tau(B0s)=1.444(+0.098)(-0.090)(stat)+/-0.020(sys) ps. We also report a measurement for the lifetime of the B0 meson using the exclusive decay B0-->J/psi(mu+mu-)K*0(892)(K+pi-). We reconstruct 1370 signal candidates, obtaining tau(B0)=1.473(+0.052)(-0.050)(stat)+/-0.023(sys) ps, and the ratio of lifetimes, tau(B0s)/tau(B0)=0.980(+0.076)(-0.071)(stat)+/-0.003(sys).
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Autermann C, Avila C, Babukhadia L, Bacon TC, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Beri SB, Bernardi G, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Bloch D, Blumenschein U, Boehnlein A, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Hauptman JM, Hauser R, Hays C, Hays J, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev V, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouchner A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magnan AM, Maity M, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin A, Schwartzman A, Schwienhorst R, Sengupta S, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev I, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Observation and properties of the X(3872) decaying to J/psipi(+)pi(-) in pp collisions at sqrt[s]=1.96 TeV. Phys Rev Lett 2004; 93:162002. [PMID: 15524981 DOI: 10.1103/physrevlett.93.162002] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2004] [Indexed: 05/24/2023]
Abstract
We report the observation of the X(3872) in the J/psipi(+)pi(-) channel, with J/psi decaying to mu(+)mu(-), in pp collisions at sqrt[s]=1.96 TeV. Using approximately 230 pb(-1) of data collected with the Run II D0 detector, we observe 522+/-100 X(3872) candidates. The mass difference between the X(3872) state and the J/psi is measured to be 774.9+/-3.1(stat)+/-3.0(syst) MeV/c(2). We have investigated the production and decay characteristics of the X(3872) and find them to be similar to those of the psi(2S) state.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Autermann C, Avila C, Babukhadia L, Bacon TC, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Beri SB, Bernardi G, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Bloch D, Blumenschein U, Boehnlein A, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Hauptman JM, Hauser R, Hays C, Hays J, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev V, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouchner A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Magnan AM, Maity M, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin A, Schwartzman A, Schwienhorst R, Sengupta S, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev I, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Search for doubly charged higgs boson pair production in the decay to mu(+)mu(+)mu(-)mu(-) in pp collisions at sqrt[s]=1.96 TeV. Phys Rev Lett 2004; 93:141801. [PMID: 15524781 DOI: 10.1103/physrevlett.93.141801] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2004] [Indexed: 05/24/2023]
Abstract
A search for pair production of doubly charged Higgs bosons in the process pp -->H(++)H(--) -->mu(+)mu(+)mu(-)mu(-) is performed with the D0 run II detector at the Fermilab Tevatron. The analysis is based on a sample of inclusive dimuon data collected at an energy of sqrt[s]=1.96 TeV, corresponding to an integrated luminosity of 113 pb(-1). In the absence of a signal, 95% confidence level mass limits of M(H(+/-+/-)(L))>118.4 GeV/c(2) and M(H(+/-+/-)(R))>98.2 GeV/c(2) are set for left-handed and right-handed doubly charged Higgs bosons, respectively, assuming 100% branching into muon pairs.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abazov VM, Abbott B, Abdesselam A, Abolins M, Abramov V, Acharya BS, Adams DL, Adams M, Ahmed SN, Alexeev GD, Alton A, Alves GA, Arnoud Y, Avila C, Babintsev VV, Babukhadia L, Bacon TC, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Baringer P, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beaudette F, Begel M, Belyaev A, Beri SB, Bernardi G, Bertram I, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Blazey G, Blekman F, Blessing S, Boehnlein A, Bojko NI, Bolton TA, Borcherding F, Bos K, Bose T, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchholz D, Buehler M, Buescher V, Burtovoi VS, Butler JM, Canelli F, Carvalho W, Casey D, Castilla-Valdez H, Chakraborty D, Chan KM, Chekulaev SV, Cho DK, Choi S, Chopra S, Claes D, Clark AR, Connolly B, Cooper WE, Coppage D, Crépé-Renaudin S, Cummings MAC, Cutts D, Da Motta H, Davis GA, De K, De Jong SJ, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doulas S, Dudko LV, Duflot L, Dugad SR, Duperrin A, Dyshkant A, Edmunds D, Ellison J, Eltzroth JT, Elvira VD, Engelmann R, Eno S, Eppley G, Ermolov P, Eroshin OV, Estrada J, Evans H, Evdokimov VN, Ferbel T, Filthaut F, Fisk HE, Fortner M, Fox H, Fu S, Fuess S, Gallas E, Galyaev AN, Gao M, Gavrilov V, Genik RJ, Genser K, Gerber CE, Gershtein Y, Ginther G, Gómez B, Goncharov PI, Gounder K, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Grinstein S, Groer L, Grünendahl S, Grünewald MW, Gurzhiev SN, Gutierrez G, Gutierrez P, Hadley NJ, Haggerty H, Hagopian S, Hagopian V, Hall RE, Han C, Hansen S, Hauptman JM, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jaffré M, Jain S, Jesik R, Johns K, Johnson M, Jonckheere A, Jöstlein H, Juste A, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Karmanov D, Karmgard D, Kehoe R, Kesisoglou S, Khanov A, Kharchilava A, Klima B, Kohli JM, Kostritskiy AV, Kotcher J, Kothari B, Kozelov AV, Kozlovsky EA, Krane J, Krishnaswamy MR, Krivkova P, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kuznetsov VE, Landsberg G, Lee WM, Leflat A, Lehner F, Leonidopoulos C, Li J, Li QZ, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipton R, Lucotte A, Lueking L, Lundstedt C, Luo C, Maciel AKA, Madaras RJ, Malyshev VL, Manankov V, Mao HS, Marshall T, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McMahon T, Melanson HL, Melnitchouk A, Merkin A, Merritt KW, Miao C, Miettinen H, Mihalcea D, Mokhov N, Mondal NK, Montgomery HE, Moore RW, Mutaf YD, Nagy E, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Nomerotski A, Nunnemann T, O'Neil D, Oguri V, Oshima N, Padley P, Papageorgiou K, Parashar N, Partridge R, Parua N, Patwa A, Peters O, Pétroff P, Piegaia R, Pope BG, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Rajagopalan S, Rapidis PA, Reay NW, Reucroft S, Ridel M, Rijssenbeek M, Rizatdinova F, Rockwell T, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Santoro A, Sawyer L, Schamberger RD, Schellman H, Schwartzman A, Shabalina E, Shivpuri RK, Shpakov D, Shupe M, Sidwell RA, Simak V, Sirotenko V, Slattery P, Smith RP, Snow GR, Snow J, Snyder S, Solomon J, Song Y, Sorín V, Sosebee M, Sotnikova N, Soustruznik K, Souza M, Stanton NR, Steinbrück G, Stoker D, Stolin V, Stone A, Stoyanova DA, Strang MA, Strauss M, Strovink M, Stutte L, Sznajder A, Talby M, Taylor W, Tentindo-Repond S, Trippe TG, Turcot AS, Tuts PM, Van Kooten R, Vaniev V, Varelas N, Villeneuve-Seguier F, Volkov AA, Vorobiev AP, Wahl HD, Wang ZM, Warchol J, Watts G, Wayne M, Weerts H, White A, Whiteson D, Wijngaarden DA, Willis S, Wimpenny SJ, Womersley J, Wood DR, Xu Q, Yamada R, Yasuda T, Yatsunenko YA, Yip K, Yu J, Zanabria M, Zhang X, Zhou B, Zhou Z, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG, Zylberstejn A. A precision measurement of the mass of the top quark. Nature 2004; 429:638-42. [PMID: 15190311 DOI: 10.1038/nature02589] [Citation(s) in RCA: 203] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2004] [Accepted: 04/21/2004] [Indexed: 11/09/2022]
Abstract
The standard model of particle physics contains parameters--such as particle masses--whose origins are still unknown and which cannot be predicted, but whose values are constrained through their interactions. In particular, the masses of the top quark (M(t)) and W boson (M(W)) constrain the mass of the long-hypothesized, but thus far not observed, Higgs boson. A precise measurement of M(t) can therefore indicate where to look for the Higgs, and indeed whether the hypothesis of a standard model Higgs is consistent with experimental data. As top quarks are produced in pairs and decay in only about 10(-24) s into various final states, reconstructing their masses from their decay products is very challenging. Here we report a technique that extracts more information from each top-quark event and yields a greatly improved precision (of +/- 5.3 GeV/c2) when compared to previous measurements. When our new result is combined with our published measurement in a complementary decay mode and with the only other measurements available, the new world average for M(t) becomes 178.0 +/- 4.3 GeV/c2. As a result, the most likely Higgs mass increases from the experimentally excluded value of 96 to 117 GeV/c2, which is beyond current experimental sensitivity. The upper limit on the Higgs mass at the 95% confidence level is raised from 219 to 251 GeV/c2.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, P O Box 79, 141980 Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|